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Symposium on "Environmental
carcinogenesis"
Aromatic amines and nitroaromatic hydrocarbons as
environmental carcinogens: metabolic activation,
carcinogen-DNA adduct formation, and methods for
adduct detection
F.F. Kadlubar
National Center for Toxicological
Jefferson, AR, U.S.A. 72079
Research,
Carcinogenic aromatic amines and nitroaromatic
hydrocarbons are widely distributed in our
environment, being present in cigarette smoke,
diesel exhaust, coal oil and shale oil effluents, and
polluted air particulates. Metabolic activation may
take place in the liver or other target tissues and
involves formation of reactive N-hydroxy
metabolites or their esterified derivatives. Specific
carcinogen-DNA adducts which result from these
pathways have now been identified for 2-
acetylaminofluorene, 1- and 2-naphthylamine, 4-
aminobiphenyl, benzidine, N-methyl-4-
aminoazobenzene, 3,2'-dimethyl-4-aminobiphenyl,
4-nitrobiphenyl, and 1-nitropyrene. Recently, we
have shown that peroxidation of aromatic amines
by the prostaglandin endoperoxide synthetase also
results in reactive metabolites that bind to DNA.
The identity of these metabolites and their DNA
adducts is currently under investigation. Studies
conducted thus far indicate that the relative
persistence in vivo of certain N2- and C8-substituted
guanine adducts and their relative mutagenic
potencies in bacterial test systems correlate well
*Honorary Secretary, Dr. M.J. Embleton, Cancer
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with tumorigenesis and are consistent with the
point mutation (G:T transversion) observed on
activation of certain cellular transforming genes.
Development of 32P reverse-labeling and
immunologic methods for detection of these
adducts in exposed population may provide a direct
assessment of human cancer risk.
Human monitoring for carcinogen exposure using
chemical methods
P.B. Farmer
MRC Toxicology Unit, Woodmansterne Road,
Carshalton, Surrey
The chemical monitoring of environmental
exposure to carcinogens requires the use of
exceptionally sensitive analytical techniques. Ideally
the reaction product between the ultimate
carcinogenic species and the crucial site in DNA
should be measured. Normally in practice the
nature of this product is not known with certainty
and, even if it were, the analysis of such a product
would be beset by difficulties caused by its in vivo
instability and the difficulties in acquiring it in
sufficient quantities for chemical analysis. Despite
this, postlabelling radiochemical techniques show
considerable promise for the sensitive detection of
DNA-carcinogen adducts. An alternative approach
for routine human monitoring might be the assay
of excreted excised DNA-carcinogen adducts, which
we are currently studying for some methylating
agents.
The reaction products between electrophilic
carcinogens and proteins are often more stable and
easier to acquire than the DNA-adducts. We have
therefore been investigating if the analysis of such
products (formed with haemoglobin) is of use for
practical monitoring of exposure to alkylating
agents. Our initial studies indicate that this is the112 PROCEEDINGS OF BACR 24TH AGM
case for exposure to some simple alkylating agents
such as ethylene oxide and propylene oxide.
However interpretation of some results is hindered
by the existence of background levels of material.
This difficulty has been overcome in experimental
systems by the use of stable isotope labelled
alkylating agents.
Detection and quantification of specific carcinogen-
DNA adducts in mammalian cells by high-affinity
monoclonal antibodies
M.F. Rajewsky
Institut fur Zellbiologie (Tumorforschung),
Universitdt Essen (GH), Hufelandstrasse 55, D-4300
Essen 1, Federal Republic ofGermany
The application of conventional radio-
chromatographic techniques to detect and quantitate
carcinogen-induced structural modifications in the
DNA of mammalian cells, is limited by the
necessity to use radioactively labelled agents and
by the relatively large amounts of DNA (cells)
required for analysis at low levels of modification.
Recently developed immunoanalytical methods
have improved this situation considerably. Thus,
high-affinity monoclonal antibodies, in combination
with radio- and enzyme-immunoassays, permit
the sensitive detection of alkyl-deoxynucleosides
in small samples of hydrolyzed DNA from
tissues or cultured cells previously exposed to
nonradioactive (e.g., environmental) alkylating
N-nitroso carcinogens (see Muller, Adamkiewicz
and Rajewsky (1982), IARC Sci. Publ. 39, 443-
459). Moreover, a standardised procedure has been
established for the use of monoclonal antibodies
to quantitate by direct immunofluorescence (and
with the aid of a computer-based image analysis
of electronically intensified fluorescence signals)
specific alkylation products in the nuclear DNA
of individual cells (Adamkiewicz, Ahrens and
Rajewsky, subm. f. publ.). With this method,
the present detection limit for, e.g., o6-
ethyldeoxyguanosine (06-EtdGuo) is of the order of
5 x 102 06-EtdGuo molecules per diploid genome.
It has, therefore, now become possible to monitor
cells (e.g., from biopsy material) directly for the
presence of specific carcinogen-DNA adducts,
or with respect to their individual capacity for
enzymatic removal of such modified structures from
their DNA prior to DNA repair. (Supported by
the Deutsche Forschungsgemeinschaft, SFB
102/A9, and by the Commission of the European
Communities, ENV-544-D[B].)
The role of viral hepatitis in human liver cancer
A.J. Zuckerman
London School of Hygiene and Tropical Medicine,
London
The evidence for the implication of hepatitis B virus
in the pathogenesis of primary hepatocellular
carcinoma is based on epidemiological and
geographical observations of a strong correlation
between hepatatis B infection and this common and
important cancer; a relatively constant risk of
developing this type of cancer in both endemic and
non-endemic areas among persistent male carriers
of hepatitis B surface antigen; infection precedes
and may accompany the development of cancer,
usually in a liver with chronic damage or
macronodular cirrhosis associated with hepatitis B
virus; hepatitis B antigens are present in the
malignant tissue and there is evidence of covalent
integration of the genome of hepatitis B virus into
the DNA of the tumour cells; several cell lines
derived from primary hepatocellular carcinoma
secrete B surface antigen in culture and DNA has
been shown to be integrated into the genome of
these cells as well as RNA molecules containing
specific sequences of hepatitis B virus and at least
one of these cell lines has been shown to be
heterotransplantable; and the finding of chronic
liver damage and primary liver cancer in several
animal species infected with viruses which are
phylogenetically related to human hepatitis B virus.
More recently, the strategy of replication of
hepatitis B virus has been shown to have marked
similarities to retroviruses, but there are also
features which have never been observed with
retroviruses.
lonising radiation in the environment--sources
and effects
A.P. Brown
National Radiological Protection Board, Chilton,
Didcot, Oxon, OXJJ ORQ
The natural and artificial sources of radiation are
briefly outlined and their relative contributions to
the population dose in the U.K. estimated. The
epidemiological evidence relating ionising radiation
to cancer induction in humans is reviewed and
some of the problems in applying these data to the
low levels of radiation in the environment arePROCEEDINGS OF BACR 24TH AGM 113
highlighted. The apparent certainty of cancer risk
factors used in radiological protection is contrasted
with the uncertainty of the underlying biological
events.
oxidation may interfere with a true assessment of
faecal mutagenicity.
Abstracts of members' proferred papers
Monitoring human body fluids for carcinogens using
bacterial mutation
S. Venitt
Institute of Cancer Research, Pollards Wood
Research Station, Nightingales Lane, Chalfont St.
Giles, Bucks. HP8 45P, U.K.
The well validated qualitative association between
mutagenicity and carcinogenicity has been
established largely by extensive use of assays
employing reverse-mutation of bacteria from
amino-acid auxotrophy to prototrophy (e.g.,
his---+his+: trp--trp+), using a diverse range
of pure chemicals. Because bacterial mutation
assays are sensitive, rapid, economical and
relatively simple to perform, they are now being
used in studies of human body fluids and excreta in
order to determine to what extent the presence of
mutagens can be implicated in the aetiology of
cancers at several sites. The assay of urine for
mutagenicity as an indicator of absorption of
carcinogens is also gaining wide acceptance.
However, the use of reverse mutation assays which
were originally designed for testing pure chemicals
for determining the mutagenicity of complex
biological mixtures is fraught with opportunities for
generating artefacts. For example, studies in this
laboratory have shown that trace amounts of
histidine and tryptophan in faecal extracts can
seriously interfere with fluctuation tests, giving
false-positive results. The same problem has been
encountered in assays of gastric juice, where, in
samples from some patients, high levels of free
amino acids have been detected. Faeces originate
and are stored in the colon, which is anaerobic.
However, of several studies of mutagenicity of
human faecal extracts now published, none has
employed anaerobic mutation assays and the effects
of air on the mutagenicity of faecal extracts has not
been controlled. We have therefore developed
methods for preparing faecal extracts and assaying
them for mutagenicity under strictly anaerobic
conditions. So far we have found that aqueous
faecal extracts prepared and assayed anaerobically
gave negative results under conditions where
reference mutagens were positive. Extracts of the
.same stool samples prepared and assayed
aerobically were positive, suggesting that air-
Pharmacokinetic and preliminary clinical toxicity
data on TGU
J.F.B. Stuart"2, J. Welsh', A. Setanoians', S. B.
Kaye' & K.C. Calman'
'Department of Clinical Oncology, University of
Glasgow, Glasgow and 2Department Of
Pharmaceutics, University ofStrathclyde, Glasgow
TGU is a new and comparatively stable epoxide
which is thought to act as an alkylating agent. It
has anti-tumour activity in a wide range of
experimental tumours and is active in
cyclophosphamide resistant P388. An HPLC
analytical method has been, developed with a
sensitivity of 10mgml-'. Pharmacokinetic data
have been obtained from male Porton mice. The
data fit a two compartment pharmacokinetic model
with a bi-exponential decay. The tia is 1.5min t-f3
5min, area under the curve (AUC)
57.74jugml-min-1, elimination constant 0.1386
and VD 0.7497ml. The patients study includes doses
up to 120mgm2 and 10 patients have received the
drug. The pharmacokinetics in 5 patients show a
short t43 and no toxicity has been experienced at
this dose of the drug.
Effects of misonidazole (MISO) on the
pharmacokinetics of 5-fluorouracil (FU) in humans
B.J. McDermott, H.W. van den Berg,' W.M.C.
Martin2 and R.F. Murphy
Departments of Biochemistry, 'Therapeutics and
Pharmacology, Queen's University of Belfast and
2Belvoir Park Hospital, Belfast
Five patients with gastrointestinal cancer received
FU (1.Ogm-2), MISO (1.75 or 2.0gm-2) and FU
(1.0gm-2), FU (1.5gm-2), MISO (1.75 or
2.Ogm-2) and FU (1.5gm-2), consecutively, at
monthly intervals. Elimination of FU and
metabolites in urine during 48h after drug
administration were analyzed using a F--specific
electrode after combustion of specimens in an114 PROCEEDINGS OF BACR 24TH AGM
oxygen flask. MISO had a potentiating effect on
the retention of total drug in 9 of the 10 courses of
treatment investigated. The areas under the "Sigma-
minus" curves (AUC) of drug elimination were
enhanced by 2-33% of those observed when FU
was given alone. Delayed clearance of FU from the
body in the presence of MISO was reflected in a
reduced extent of urinary excretion of total drug
during 6 courses of therapy. The anomalous trends
in excretion parameters may be explained by the
clinical conditions. Patient toxicity during 5 of the
treatments corresponded with the highest AUC
values. These findings are a preliminary indication
that MISO may have an effect on drug
pharmacokinetics in humans. Furthermore, the
mechanism of MISO potentiation of FU action
cannot be a competition for microsomal enzymes,
as proposed for the interaction of MISO and
alkylating agents, since FU is catabolized at
mitochondrial and cytosolic sites.
Pharmacokinetics of etoposide (VP) in patients with
small cell lung cancer
J. Edmundson, N. Thatcher, P.M. Wilkinson, J.
Margison, W. Steward, W. Chiu & J. Wagstaffe
Departments of Medical Oncology and Clinical
Pharmacology, Christie Hospital, Manchester M20
9BX
VP alone or in combination is now used extensively
for the management of small cell lung cancer
(SCLC), but at present there is no definitive dose
schedule. We therefore determined the kinetics in
17 patients with (SCLC). VP was administered in 3
doses of 125, 300 and 600mgm-2 in 500ml
N.saline over 30 min.
Patients given the first dose also received
cyclophosphamide (C) 2.5gm2 i.v. Results are
summarised in the Table.
Dose mgm-2 125 300 600
Parameter
(mean +s.e.)
Toc(min) 22+5.4 12+5 20+2.4
Tift(h) 5.3+1 4.5+95 6.1+1.5
AUC(pgl'-h-1) 84+9.8 255+23 591 +83
CL (mlmin-1) 48±8.5 33.23+3.3 32.6+5.1
incremental dose increase produced the expected
linear increase in AUC but not drug distribution or
clearance. There was no evidence to suggest that
the rate of biotransformation of C was altered by
VP. The results suggest that a single bolus dose
may be as effective as fractionated bolus schedules.
Pharmacokinetics of cis-diammine-1,1-cyclobutane
dicarboxylate platinum II (CBDCA, JM8) in
patients with normal and abnormal renal function
S.J. Harland, D.R. Newell, Z.H. Siddik, R.
Chadwick, A.H. Calvert & K.R. Harrap
Inst. Cancer Res. and Royal Marsden Hosp., Sutton,
Surrey, England
CBDCA is an analogue of cisplatin which is free of
the nephrotoxicity (Calvert et al., (1982), Cancer
Chemother. Pharmacol. 9, 3) but appears to retain
the efficacy. Its limiting toxicity is haematological
and patients with poor renal function are
particularly susceptible to this.
The pharmacokinetics following a 1 h infusion
were studied in patients receiving doses between 20
and 520mgm 2. Renal function was assessed in
every case by 5'Cr EDTA clearance. Total plasma
platinum (Pt) and free Pt (in plasma ultralfiltrate)
were measured by atomic absorption
spectrophotometry. Intact CBDCA was measured
by HPLC. There was a linear relationship between
dose and area under the plasma concentration
curve (AUC) for total Pt. Protein binding during
the first 4h was between 0 and 28%. It rose to 85-
95% by 24h. All the free Pt was in the form of
CBDCA during the first 4h. An early elimination
phase for free Pt had a half-life of 91 +6 (s.e.)
mins, similar to that for CBDCA and total Pt.
Later half-lives of 279+24 min and >24h were
seen for free and total Pt respectively. 65+1% of
the administered Pt appeared in the urine over the
first 24h. Patients with poor renal function have
higher AUCs for total Pt. Both renal and total
clearance of free Pt correlated significantly with
glomerular filtration rate. These findings justify the
practice of reducing the dose of CBDCA in the
presence of renal impairment.
Renal clearance of free Pt following CBDCA was
0.67+0.05 5'Cr EDTA clearance, suggesting that
there was no tubular secretion of the drug as occurs
with cisplatin (Jacobs et al., (1980), Cancer Treat.
Rep. 64, 1223). This may account for the difference
in nephrotoxicity.
In all instances an open 2 compartment model
would fit the observed serum concentrations. ThePROCEEDINGS OF BACR 24TH AGM 115
Plasma levels of N-methylformamide following
intravenous and oral administration in man
C. Brindley, P. Kestell, A. Gescher and J.A. Slack
CRC Experimental Chemotherapy Research Group,
University ofAston, Birmingham
N-Methylformamide (NMF, NSC 3051) is a stable,
water soluble liquid with a remarkably wide
spectrum of antitumour activity in mice (Gescher et
al. (1982), Br. J. Cancer, 45, 843). One of the most
attractive properties of NMF which led to the
renewed interest in its clinical applicability is the
complete absence of deleterious effects on the bone
marrow in experimental animals (e.g. in mice:
Langdon et al., unpublished). However, in a clinical
trial in 1956 NMF caused symptoms of
hepatotoxicity in the seven patients treated (Myers
et al. (1956), Cancer, 9, 949). As part of Phase 1
studies carried out at the Dutch Cancer Institute,
Amsterdam (G. McVie) and Charing Cross
Hospital (E. Newlands) concentrations of NMF in
the plasma of patients were measured by gas-liquid
chromatography. Six patients with a variety of
malignancies received either 300, 600 or
1200mgm-2 NMF by both i.v. infusion and p.o.
administration with fruit juice. Peak plasma levels
of NMF after infusions of 600mgm-2 NMF in
two patients were 13.1 and 20.5ygml-1, and peak
plasma levels after oral ingestion of 600mgm-2
NMF were 15.0 and 13.4pigml-'. Twelve h after
administration NMF plasma levels had declined to
37.6+23.5% of peak concentration in all patients.
When the areas under the plasma concentration of
NMF vs time curves (calculated from the time of
administration to either 12h or 24h after
administration) after i.v. and p.o. administration
were compared, the bioavailability values (190%,
290%, 170%, 60%, 70% and 180%) were found to
be very variable. It appears however that in further
clinical trials to evaluate the antitumour efficacy of
NMF the drug can be given orally.
Platinum-induced emesis-the effect ofescalating
doses of metoclopramide (M)
S.G. Allan, M.A. Cornbleet, P.S. Warrington, S.P.
Lockhart, R.C.F. Leonard & J.F. Smyth
Department of Clinical Oncology, Western General
Hospital, Edinburgh
It has recently been claimed that high doses of M
convey significant protection against platinum-
induced emesis. The aims of this study are to
examine: (1) the differences in anti-emetic effect of
escalating doses of M, and (2) the difference in side
effects of M at these dose levels. In a double blind,
randomised, prospective study, M was given by 2
hourly 100ml infusions x 5 starting "hour prior to
cis-platinum infusion. 35 patients have been entered
to-date. The mean age was 52 (18-70) and patients
received cis-platinum alone or in combination for
various tumours (ovary, bronchus, teratoma,
bladder and melanoma). 17 patients have
completed treatment at each of three dose levels of
M, 3mgkg-1 (low dose, LD), 5mgkg-1 (moderate
dose, MD) and lOmgkg-1 (high dose, HD). A
total of 61 courses have been evaluated, 19 at LD,
21 at MD and 21 at HD. M was tolerated well at
all dose levels. 1 patient at HD and 1 at MD had
easily reversible extra-pyramidal reactions and 11
patients (6 on LD) had mild drowsiness. Nausea
was abolished in 5% of patients on LD, 19% on
MD and 19% on HD. Vomiting was abolished in
5% of patients on LD, 19% on MD and 14% on
HD. Diarrhoea was not increased at the higher
doses. To-date it would appear that the side effects
of M are not increased at the higher doses. This
double blind trial continues and data will be
presented on at least 35 patients (>100 treatment
courses) together with a statistical analysis of the
apparent improved effect of doses of M in excess of
3mgkg-'.
An evaluation of prednisolone as an appetite
stimulant in cancer patients
J.C. Willox1, J. Corr2 & K.C. Calman'
'Department ofClinical Oncology, Gartnavel General
Hospital, Glasgow and 2Department of Dietetics,
Gartnavel General Hospital, Glasgow
Cancer patients, at all stages of their disease
complain frequently of anorexia. Prednisolone has
been used empirically, for many years to improve
well-being and stimulate appetite in cancer patients
with advanced disease. This study examined the
effect of prednisolone against placebo on the
appetite, body weight, food intake and general well-
being of 41 oncology out-patients. The patients had
a variety of solid tumours; ages ranged from 27 to
80y (mean 60y) with male:female ratio 16:25.
Eighteen of the patients received regular
chemotherapy which coincided with the study
timings. The study was double-blind and each
patient received an initial two week course of
tablets-prednisolone (5mg) or placebo-I tablet116 PROCEEDINGS OF BACR 24TH AGM
t.i.d. and then the alternative tablets for a further
two weeks. Assessment was by completion of visual
analogue scales and answers to questions on
appetite, well-being and nausea. A 24-hour dietary
recall history was taken and analysed for calorie
and protein content. Anthropometric measurements
of weight and skinfold thickness were taken.
Results show that 82% patients reported improved
appetite when commenced initially on prednisolone.
This' compares with 50% patients who found
benefit from initial placebo tablets. Of the 82%
with improvement on prednisolone, only 60%
maintained this when crossed over to placebo. The
50% placebo responders increased to 78% when
crossed over to prednisolone. This appetite
improvement was reflected in an improved food
intake on prednisolone initially (69%) compared to
placebo (56%). Weight gain, however, showed little
difference between groups. In conclusion, the
results indicate an improvement in appetite and
food intake for a majority of patients when taking
prednisolone. Further studies are required to
evaluate long term use ofprednisolone.
Pilot study of multiple modality therapy for advanced
ovarian adenocarcinoma
G.J.S. Rustin, B. Southcott, M. Glaser, D. Parker,
E.S. Newlands, R.H.J. Begent & K.D. Bagshawe
Departments ofMedical Oncology and Radiotherapy,
Charing Cross Hospital, London W6 8RF
Despite dramatic reductions in tumour bulk by
surgery and chemotherapy the percentage of
patients with advanced ovarian adenocarcinoma
who become long term survivors is small.
Radiotherapy has been shown to improve survival
of patients with minimal residual disease following
surgery (Dembo et al. (1979), Am. J. Obstet.
Gynecol., 134, 793). A pilot study on 15 women has
therefore been performed to determine the
feasibility of giving multiple modality treatment for
Stage III and IV ovarian adenocarcinoma.
Successful initial debulking surgery has been
performed in 13 patients. Eleven patients have so
far completed 4 courses of cis-platinum lOOmgm-2
alternating with 4 courses of cyclophosphamide and
methotrexate over a mean of 13 weeks. At second
look surgery 7 patients were macroscopically in
complete remission, 3 were partial responses and 1
had stabilisation of disease. The 9 patients with
<1 cm maximum diameter residual disease then
received a mean of 2507 cGy whole abdominal
irradiation in 20-25 fractions over 23-38 days. No
treatment was then given until relapse. The
actuarial median survival has not been reached by
95 weeks. Two of the 9 patients who completed all
treatment have died, 2 are alive with disease and 5
are disease free. No long term toxicity has been
observed. As this study is of comparable toxicity to
other currently used regimens, but of shorter
duration, a randomised trial is now indicated to
determine whether this approach can increase the
percentage of long term survivors.
Phase I studies with CB3717 (N-(4-(N-amino-4-
hydroxy-6uinazolinly)Methyl)prop-2-
ynylamino)benzoyl)-L-glutamic acid)
A.H. Calvert, D.L. Alison, S.J. Harland, A.L.
Jackman, C.J. Mooney, I.E. Smith & K.R. Harrap
Department of Biochemical Pharmacology, Institute
of Cancer Research, Sutton and The Royal Marsden
Hospital
CB3717 has been used to treat 50 patients with
advanced malignant disease. Initially doses were
infused over 1 h. The toxicities observed using this
schedule were rises in -the plasma transaminase
levels, generalised malaise, occasional skin rashes
and myleosuppression. The most consistently
observed toxicity was the rise in the plasma
transaminase levels which occurred in
approximately half the patients. Animal studies
suggested that this could be due to high biliary
concentrations of CB3717 giving rise to
intracanalicular precipitation of the drug. The use
of a 12h infusion of CB3717 was therefore also
investigated in patients. Doses of CB3717 were
escalated from 140-550mgm-2. Dose limiting
toxicity has not yet been reached. Rises in plasma
transaminase levels occurred following treatment
with either protocol with approximately equal
frequency. No dose response relationship has yet
been observed between the dose given and the
magnitude or the frequency of the rise in plasma
transaminases. Rises in plasma phenylalanine levels
were also noted and could be due to inhibition of
biopterin dependant phenylalanine hydroxylation.
Skin rashses were observed which were
erythematous or maculopapular and itchy and were
usually confined to the trunk or legs. Other
antifolates (eg metoprin) may cause rashes due to
elevated histamine levels, due to inhibition of
histamine degradation. Studies of CB3717 and
related quinazolines showed that although
compounds in the 2,4-diamino series were inhibitors
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series (including CB3717) were not. Plasma
histamine levels were not elevated. When
myleosuppression occurred the white count nadir
was 12 days after treatment, and recovery occurred
over a few days. Four partial responses were seen,
2 in patients with breast cancer, both heavily pre-
treated, one in carcinoma of the ovary, and one in
large cell adenocarcinoma of the bronchus. Minor
clinical responses have also been seen in patients
with ovarian cancer, breast cancer, bowel cancer
and adenocarcinoma of the bronchus. It has been
notable that clinical responses seem to occur in
patients who had rather slowly progressing tumours
which had been resistant to multiple other forms of
therapy.
High dose and conventional dose ellipticine (E) in
advanced ovarian and breast cancer
A.L. Harris', S. Raju, S. Ziddik, D. Spence, E.
Wiltshaw, I.E. Smith & R. Levy
1Clinical Oncology, Newcastle Hospital and Royal
Marsden Hospital, Fulham Road, London
E is a plant-derived intercalating agent that does
not cause alopecia or neutropenia. The usual dose
is 100mgm-2 i.v. weekly. Antibodies to the drug
occur. Thirteen patients with advanced post-
menopausal breast cancer resistant to endocrine
therapy and adriamycin were treated on the weekly
schedule. There were 2 partial responses (soft tissue,
bone). Three patients stopped treatment because of
severe weakness after 3 courses. All patients had
dry mouths and 4 had severe vomiting. Seven
patients with advanced ovarian cancer (Stage III,
IV) resistant to cis platinum received 300mgm-2 E
3-weekly. All patients had normal plasma creatinine
before treatment. Two days after E, creatinine rose
to 132-3044umol1-1, peaking at day 2-8. Urine
NAG and ,B2 microglobulin rose 2-3-fold. Thus
nephrotoxicity prevented the use of the high dose
regimen. Antibody titres to E were measured before
each course of treatment and ranged from 1/16 to
1/1024 in 10/20 patients. One patient developed
severe intravascular haemolysis 1 hour after the 5th
course of E (100mgm-2) (antibody titre 1/64).
Antibody titre was not predictive of haemolysis.
Although E is active in adriamycin resistant
breast cancer, the side effects are severe and limit
its utility.
LHRH analogue treatment for adenocarcinoma of
prostate
J.M. Allen, J.P. O'Shea, G. Williams & S.R. Bloom
Department of Medicine and Urology, RPMS,
Hammersmith Hospital, Du Cane Road, London,
W12 OHS, U.K.
Twelve patients with advanced progressive
adenocarcinoma of prostate have been treated for
at least 3 months with a long acting decapeptide
analogue of gonadotrophin releasing hormone
(LHRH), ICI 118, 630. Five patients had either
prdviously failed to respond or relapsed on
conventional endocrine therapy. Of these, two have
achieved remarkable symptomatic improvement
being able to withdraw from narcotic analgesia.
The remaining three patients failed to respond to
the analogue. Seven patients with histological grade
III tumours received the LHRH analogue as first
choice. One of these patients presented at an
advanced stage with a pathological fracture of the
humerus, and has shown only slight improvement.
The remaining 6 patients have all responded to
treatment in terms of symptomatic relief of pain,
clinical regression of tumour and normalisation of
tartrate labile acid phosphatase. Endocrine
assessment in these patients has shown a rise in
serum LH, FSH and testosterone over the first 5
days of treatment. Levels of gonadotrophins and
testosterone are significantly suppressed two weeks
after starting treatment and remain low thereafter.
The LHRH analogue appears a potent
treatment for endocrine responsive tumours such as
adenocarcinoma of prostate. It offers advantages
over conventional therapy such as stilboestrol as it
appears a more specific and effective suppressant of
testosterone and gonadotrophins.
VP16-213 infusions for the treatment of metastatic
lung cancer
W.P. Steward, N. Thatcher, W. Shiu, J. Wagstaffe
& D. Crowther
C.R.C. Department of Medical Oncology, Christie
Hospital, Manchester, U.K.
Twenty-five patients with extensive stage lung
cancer (9 small cell, 5 squamous cell, 10
undifferentiated and 1 adenocarcinoma) were given
24h infusions of VP16-213 at a dosage of
600mgm 2 repeated three weekly. Visceral118 PROCEEDINGS OF BACR 24TH AGM
metastatic sites included liver (ten patients) and
bone (four patients). Karnofsky performance before
treatment was a median of 60% with a range of 40
to 80. Eight patients had previously been given
radiotherapy.
Seventy-three infusions were administered to the
total patient group. A median of 3 courses (range
1-6 courses) was given. Three patients received only
one course and three had five courses or more.
Two partial responses were obtained, 6 patients
had static disease, and 17 patients progressed
despite treatment. In 15 of the patients there was
an improvement in the Karnofsky performance.
The median survival from the start of treatment
was 2 months (range 1-18 months).
Five patients had severe myelotoxicity and there
was one death due to septicaemia.
It is considered that VP16-213 administered at
this dosage by infusion is not an effective agent for
the treatment ofmetastatic lung cancer.
Primary therapy for poor prognosis small cell
carcinoma of bronchus (SCCB) with vindesine and
VP-16-213
A. Gregor, M.A. Cornbleet, S.G. Allan & J.F.
Smyth
Department of Clinical Oncology, Western General
Hospital, Edinburgh
Despite significant improvement in the overall
management of patients with SCCB, the prognosis
for patients presenting with hepatic or CNS
metastases + poor performance status (PS) is
particularly poor. To evaluate a new drug
combination, we have entered 31 previously
untreated patients with biopsy proven SCCB,
unsuitable for intensive multimodality therapy into
this phase II study. Entry criteria included age up
to 75 and PS.4. Following staging with marrow
aspiration, bone. and brain scans and liver
ultrasound, 23 patients had extensive disease (12
liver, 8 marrow, 2 brain) and 17 patients had
multiple sites involved. Vindesine 3mgm2 day 1,
and VP-16-213 120mgm-2 days 1-3 were given i.v.
every 21 days x 6. Twenty-eight patients-19 men, 9
women, mean age 63.7 (range 44-73)-are
evaluable. 19/28 (68%) patients responded (3
complete), all seen by 9 weeks. 100% limited and
55% extensive disease patients responded, including
6/12 with hepatic involvement. Apart from alopecia
(all patients) toxicity was mild. Only one patient
developed haematological toxicity, WHO grade III.
Gastrointestinal and neurotoxicity were minimal.
Median survival is 3.5 months for non-responders
and 5+ (not yet reached) for responding patients.
This combination provides effective, non-toxic
palliation in a substantial proportion of SCCB
patients presenting with poor prognostic features.
Studies on the drug sensitivity of human glioma cell
lines in culture
S. Merry, R.I. Freshney & S.B. Kaye
Department of Clinical Oncology, University of
Glasgow, GJ2 9LY
Continuous cell lines have been established from 6
individual cases of human glioma, and their
sensitivity to 6 drugs (actinomycin D, adriamycin,
5-fluorouracil, melphalan, vincristine and VP16-
213) has been established. Cells were seeded onto
microtitre plates and, after 72h, were exposed to
drugs for a further 72h followed by a recovery
period of 120h. Cell number at the end of this
period was determined by the incorporation of
labelled amino acid into the perchloric acid
insoluble material derived from the cells (R.I.
Freshney, J. Paul & I.M. Kane (1975), Br. J.
Cancer, 31, 89) and by Coulter counting. The range
of ID50 values obtained for each drug was:
actinomycin D<6 x 10-64 x 10-8M; adriamycin
6x10 8-5x10-6M; 5-fluorouracil 5x10-6-
1.7 x 10-4M; melphalan 8 x 10-7-2.5 x 10-4M;
vincristine 6 x 10-9-3 x 10-5M and VP16-213
3 x 10 17-.9 x 10-4M. Cross-sensitivity and
resistance was seen for 3 drugs i.e. actinomycin D,
adriamycin and VP16-213, but not for other drugs.
Incubation of cells with labelled drug has shown
that the net uptake of actinomycin D proceeds at a
rate at least four times as great in a sensitive cell
line as it does in resistant cell lines. Further studies
on transport using radiolabelled adriamycin are in
progress. The evidence to date suggests that
patterns of cross-resistance seen in several animal
tumours also apply to some human tumours in
culture. The underlying mechanism may relate to
changes in drug influx and/or efflux as has been
demonstrated in animal tumours, and may provide
a rational basis for therapy aimed at circumventing
the tumour cell resistance which is observed
clinically.PROCEEDINGS OF BACR 24TH AGM 119
Culture and drug sensitivity of human lung tumours
in the clonogenic assay system
A.P. Simmonds', P.S. Hamilton' & K.G.
Davidson2
'Biochemistry and 2Cardiothoracic Surgical Unit,
Royal Infirmary, Glasgow
Forty eight samples of lung tumours obtained at
thoracotomy have been received for clonogenic
assay. Of the 44 presently assessed, 39 have positive
pathology and have been cultured in the double
layered agar system with mouse spleen conditioned
medium. Drig sensitivity has been evaluated using
1 h exposures to the drugs vindesine and cis-
platinum, both in current use for inoperable non
small cell cancer of the lung. Assessment of in vitro
response was made using the parameters of Salmon
et al. (Cloning of Human Tumour Stem Cells: 1980:
Alan R. Liss) with a minimum of 30 colonies per
plate accepted in controls for significant drug
results. Predominant in tumour pathology were
squamous (22/39), the remainder being
adenocarcinomas, with the exception of 1 sarcoma
and 2 oat cell carcinomas. Twenty-six of the 39
samples were cultured successfully (66%).
Surprisingly, in view of tumour site, contamination
rate was low (2/39). Plating efficiencies ranged from
<0.01% up to 0.16% but were predominantly low.
Consequently, significant drug results were obtained
in only 10 cases, although a further 4 samples had
high plating efficiencies but insufficient cell yield.
Sensitivity to vindesine was exhibited in 7/10 (70%)
of samples, the remainder being resistent.
Strikingly, however, only 1/10 (1%) showed
sensitivity to cis-platinum, 3 being intermediate,
and the remainder 6/10 (60%) were resistant. The
sample sensitive to cis-platinum was also sensitive
to vindesine. No relationship was observed between
tumour pathology and growth patterns or drug
response. In addition, tests to establish the need for
conditioned medium and comparison of methods of
disaggregation were equivocal.
Results obtained in short-term assay using nucleotide
incorporation for the in vitro prediction of
chemosensitivity of ovarian tumours
A. Wilson, C. Taylor, B. Laher, C. Newman, C.
Ford & A. Howell
Department of Obstetrics & Gynaecology,
Withington Hospital, Manchester U.K.
Cell suspensions obtained from human ovarian
B.J.C. F
tumours were exposed to various concentrations of
adriamycin (ADM) for 3h, and the effect of the
drug was quantified using depression of [3H]-uridine
incorporation. The methodology was essentially
that described by Volm et al. (Eur. J. Cancer
(1979), 15, 983), and the aim of the investigation
was to confirm the West German group's findings,
particularly that ADM sensitivity in vitro indicates
a chemoresponsive tumour. Using a cut-off point of
<60% of control at 20pgml-1 of ADM 10/23
(43%) tumours were sensitive. Clinical response to
treatment with cis-platinum correlated with in vitro
sensitivity to ADM in 5/8 (62.5%) cases. When
P388 cell lines which were sensitive (S) and resistant
(R) to ADM were tested in the same way the assay
did not show a difference between the cell lines, nor
could a dose-response curve be obtained. Non-
specific binding (NSB) of radioactivity to filters and
low viabilities were found to be responsible for this.
When the assay was modified to eliminate NSB and
maintain viability, reproducible dose-response
curves were obtained which showed a difference
between the S and R cell lines. Use of the modified
assay for human tumours has demonstrated its
increased sensitivity. In validation of the assay
results of technical artefacts suggests that the level
of correlation obtained with the original
methodology is not significant, although of the
same order as that reported by other studies.
DTIC: an appropriate clinical alternative
D.E.V. Wilman
Department of Biochemical Pharmacology, Institute
ofCancer Research, Sutton, Surrey
Over the years considerable efforts have been made
in the search for a suitable clinical alternative to
DTIC. Whilst the initial reason for this was to
overcome DTIC's photolability, improved clinical
procedures and newer photochemical investigations
have now rendered the problem of lesser
importance.
Our own investigations have produced an
extensive structure-activity series of photostable
aryltriazenes. This has led to the conclusion that
the necessary requirements for antitumour activity
in this class of compounds are a carrying group at
N1, a methyl group at N3 and a readily
metabolisable group also at N3. Triazenes of this
type may then undergo metabolism to produce a
cytotoxic monomethyltriazene.
Xenograft testing of selected examples of these
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against a Grade IV astrocytoma. In particular, 1-(4-
carbamoylphenyl)-3-methyl-3-pentyltriazene (CB10-
350) is active in this system when the tumour is
transplanted in the flank or intra-cerebrally,
whereas DTIC has no effect on the intra-cerebral
tumour. The NCI have demonstrated similar
compounds, especially 1-(4-carbamoylphenyl)-3-
ethyl-3-methyltriazene (CB10-335), to have marked
activity against colon and lung tumour xenografts.
Experimental antitumour activity alone is not
sufficient for the selection of a drug for Phase I
clinical trial. The high lipophilicity of the 4-
carbamoylphenyltriazenes, a necessity for
penetration of the blood-brain barrier, makes for
difficulties in formulation. Recent metabolic results
(C.J. Rutty, pers. comm.) suggest that a
dialkyltriazene may not be a suitable clinical
candidate, but rather an analogue not requiring
oxidative metabolism would be more effective.
Synthesis and properties of a new bicycic antitumour
agent (CCRG 81010; M&B 39565)
M.F.G. Stevens', J.A. Hickman', R. Stone', N.W.
Gibson' and E. Lunt2
'CRC Experimental Chemotherapy Group,
Department of Pharmacy, University of Aston in
Birmingham and 2May & Baker Ltd., Dagenham,
Essex
and in vitro. The intact drug is not an alkylating
agent: it has curative properties against the TLX5
lymphoma, a tumour insensitive to alkylating
agents of the P-chloroethylamine type, and L
1210/cyclophosphamide. The drug is stable at acid
pH values but degrades in alkaline conditions. At
pH 7.4 in phosphate buffer the drug has a t4 of
98min.
CONH2
CCRG 81010
M&B 39565
The relationship between melanogenesis and response
to chemotherapy in human malignant melanomas
xenografted into athymic mice
S. Sparrow
Toxicology Unit, Medical Research Council
Laboratories, Woodmansterne Road, Carshalton,
Surrey
CCRG 81010 or M&B 38565 is a bicyclic
heterocycle with broad spectrum antitumour
activity. The novel framework imidazo[5,1-d]-
1,2,3,5-tetrazine ring-system evolved following long-
term chemical investigations on cyclic and acyclic
moeities bearing NNN bonds and bicyclic systems
with bridgehead N atoms; the crucial peripheral
substituents were identified following recent
extensive biochemical investigations on the mode of
action of the clinically-used agents DTIC and
BCNU.
The drug is synthesised by interaction of 5-
diazoimidazole-4-carboxamide and 2-chloro-
ethylisocyanate in ethyl acetate at 30° in the
dark (95% yield) and has pronounced activity
against the NCI panel of mouse tumours (L 1210,
P 388, LL, C 38 and B 16). The inhibitory activity
against advanced solid mouse tumours (M 5076,
ADJ/PC6A) is particularly noteworthy and the
drug inhibits both the primary LL tumour and its
pulmonary metastases and is markedly superior to
DTIC in both cases. The drug shows some
similarities to DTIC and BCNU in its spectrum of
activity but exhibits distinctive properties in vivo
Five human malignant melanomas were serially
passaged in nude mice and only minor
morphological changes noticed at different
passages. One tumour was partially pigmented
(0.05% of cells showing melanin by light
microscopy) and four were amelanotic. Tumour
volume doubling times varied from 7-10.5 days.
The xenografts were treated with CB10-286 (a
dimethyl phenyl triazene) by injecting the mice
intraperitoneally at a dose rate of 40mgKg-' (ten
treatments in a period of 4 weeks). The partially
pigmented tumour showed a total inhibition of
growth and became very melanotic (7.5-33% of
cells with melanin). This was accompanied by an
increase in cell size and a loss of structural
morphology. No mitotic figures were seen in these
treated tumours. Two of the amelanotic tumours
also showed some reduction in growth rates as a
result of treatment. This was accompanied in both
cases by the appearance of small numbers of
pigmented cells and a reduced mitotic index. The
two remaining amelanotic tumours showed no
response to treatment either in terms of growth rate
or the appearance ofpigmented cells.PROCEEDINGS OF BACR 24TH AGM 121
A number of workers have demonstrated an
inverse relationship between proliferation and
pigmentation of melanoma cells in vitro (Sheridan
and Simmons (1981), Br. J. exp. Path., 62, 289) but
the biosynthesis of melanin is still unclear. A
number of promoting and inhibiting factors have
recently been proposed (Pawelek et al. (1980),
Nature, 286, 617) and a relationship between these
factors and tumour growth could have profound
implications for the treatment of malignant
melanoma.
17f oestradiol modulates the response of human
breast cancer cells to methotrexate
R. Clarke1, H.W. van den Berg2 and D.G.
Kennedy'
'Departments ofBiochemistry and 2Therapeutics and
Pharmacology, The Queen's University of Belfast,
Northern Ireland
The modifying influence of 17,B oestradiol (E2) on
the antimetabolic and growth inhibitory effects of
methotrexate (MTX) has been investigated in two
human breast cancer cell lines which differ in their
steroid hormone receptor content and oestrogen
responsiveness. The MDA-MB-436 cell line
synthesises low levels of oestrogen receptor and is
unresponsive to the hormone. In this cell line, E2,
(10-10-10-6M) tended to reverse the antimetabolic
action of MTX, an effect which became significant
at 10-6M E2. 10-6M E2 also reduced the anti-
proliferative action of MTX such that
approximately twice the concentration of MTX was
required to inhibit cell proliferation to the same
extent as was observed following exposure to MTX
alone. This partial reversal of response to MTX
correlated with a 20% reduction in steady state
intracellular drug concentration when cells were
exposed to 10-7M 3H-MTX in the presence of
10-6M E2. In contrast to these results, E2 (10-8-
10-6M) potentiated the action of MTX towards
the MCF-7 cell line which synthesises high levels of
the hormone receptor and is oestrogen responsive.
We conclude that the influence of E2 on the
cytotoxicity of MTX is dependent on the steroid
receptor status of the target cell. This may have
important consequences for combined hormone-
drug therapy of human breast cancer consisting of
a population of tumour cells heterogeneous with
respect to steroid hormone responsiveness and
receptor content.
Effects of adriamycin on the membrane potential of
L1210 cells
S.B. Chahwala, J.A. Hickman & R.G. Grundy
CRC Experimental Chemotherapy Group,
Department of Pharmacy, University of Aston,
Birmingham B4 7ET
The antitumour activity of adriamycin has been
related to its intercalating ability in double-stranded
DNA (Di Marco et al. (1974), Antibiot, 3, 107). In
addition to its antitumour activity, adriamycin is
cardiotoxic, eliciting ouabain like effects on the
heart. Recently targets other than DNA, in
particular the cell membrane have been proposed to
explain the cytotoxic and cardiotoxic properties of
adriamycin (Schwartz (1979), Adv. Cancer
Chemother., 1, 1). In an effort to extend the studies
of adriamycin induced membrane perturbations, we
have looked at its effects on the membrane
potential (T) of L1210 cells. The (T) was chosen
because changes in (I) may reflect changes in ion
flux across the membrane and also because (T)
changes have been implicated with cell division
(Sachs et al. (1974), Exp. Cell. Res., 83, 362).
Measurements of (T) were obtained by following
the accumulation of the lipid-soluble cation
triphenylmethylphosphonium (TPMP+) into L1210
cells. The resulting (T) was -80 mV, comparable
to values reported by (Kiefer et al. (1980), Proc.
Nat. Acad. Sci. U.S.A., 77, 2200) for murine spleen
lymphocytes. The cytotoxic concentration of
adriamycin (2.6 x 10 7M) which gave 90% cell kill
after 1 h incubation, depolarised (T) by 8mV after
1 h. The known cardiac glycoside ouabain (Na+-
K+ ATPase inhibitor) at 1 mM depolarised (T) by
12mV. Furthermore, in the assay for Na+-K+
ATPase activity in the L1210 cells, adriamycin
(2.6 x 10 7m) and ouabain (1 mM) respectively
caused 13% and 50% inhibition after 1 h. In
conclusion, it is seen that the activity of the Na+-
K+ ATPase does not make a significant
contribution to the (I) of L1210 cells and that the
observed differences in activity between adriamycin
and ouabain contradicts a proposed common
mechanism (Gosalvez et al. (1979), Cancer Res. 39,
257).122 PROCEEDINGS OF BACR 24TH AGM
Metabolic effects of cytotoxic drugs in tumour-
bearing animals
G.E. Raines1, J.C. Willoxl, G.B.S. McDonald1, J.
Irvine1, D. Doyle2 & K.C. Calman
1Department of Clinical Oncology, University of
Glasgow, Glasgow and 2Department of
Neuropathology, Southern General Hospital,
Glasgow
Aspects of host metabolism and morphology were
studied in Wistar rats bearing a sensitive cachectic
Walker 256 tumour receiving an LD1O dose of
either cis-platinum or cyclophosphamide. Animals
were divided into four groups. Group 1 had tumour
alone, Group 2 had tumour and drug, Group 3 had
drug alone whilst Group 4 had neither tumour nor
drug. Body weight and tumour size were monitored
during the study and the final tumour weight noted
on culling when blood was withdrawn for ketones
and albumin determinations. Groups were
subdivided for histochemical and e.m. assessment
which were performed on the heart, liver, kidney
and gastrocnemius and soleus muscles. Total body
nitrogen and water content were measured in intact
carcases.
The most notable observations were (i) the
decreasing tumour size in Group 2 following drug
administration, (ii) the evident loss of body
nitrogen in Group 1 and maintenance in Group 2,
(iii) the reduction of blood ketone levels in Group
2, (iv) the altered albumin concentrations between
Groups 1 and 2, and (v) the abnormal
histochemical and e.m. results in the different
groups.
In conclusion, therefore, the tumour alone group
displayed a number of distinct metabolic and
morphological abnormalities, some of which were
alleviated or reverted to normal with drug
administration, and that the drugs themselves
affected host metabolism and morphology.
Studies on the hepatotoxicity of the antitumour agent
N-methylformamide in mice
H. Whitby, A. Gescher & L. Levy1
CRC Experimental Chemotherapy Research Group
and 1Department ofOccupational Health and Safety,
University ofAston, Gosta Green, Birmingham
The antitumour agent, N-methylformamide (NMF),
which is currently undergoing phase 2 clinical trial,
has been shown to be hepatotoxic in man (Myers et
al. (1956), Cancer, 5, 949) and in rats (Lundberg et
al. (1981), Toxicology, 22, 1). We have investigated
the effect of NMF in livers of male Balb/C mice in
vivo and in vitro. Ten out of twelve livers from mice
injected with NMF 400mgkg-1 i.p. for 5 days (the
optimum antitumour dose regimen) showed
evidence of toxicity. Histopathological examination
of 7 of these livers showed areas of varying degrees
of necrosis. Total glutathione (GSH) in five of the
livers of treated animals was estimated, as changes
in GSH status after single doses of NMF have been
reported previously (Gescher et al. (1982), Br. J.
Cancer, 45, 843). No significant differences in liver
GSH were noted between NMF mice
(7.021umolg- I liver) and control mice
(6.93limolg1 liver). Incubation of isolated mouse
hepatocytes with 7mM NMF resulted in a
significant reduction in total intracellular GSH after
80 min when compared with controls. GSH levels
were reduced by 64.6+ 18.9% (n= 11). Lipid
peroxidation, as measured by malondialdehyde
formation, was markedly increased on incubation
of hepatocytes with 7mM NMF for 180 and
240min. Such delayed changes tend to suggest that
a NMF metabolite may be responsible. The in vitro
biochemical effects may be relevant to the in vivo
hepatotoxicity produced by NMF. However, the
different effects on GSH levels in vitro and in the
multidose in vivo experiment suggest that other
mechanisms, not implicating a reactive metabolite,
may also be involved.
nenznrnazole-cnemosensitzanon
pharmacokinetics
iand
P. Workman, P.R. Twentyman, F.Y.F. Lee, M.I.
Walton, L.N. Owen1 & R.A.S. White1
MRC Clinical Oncology Unit and 1Department of
Clinical Veterinary Medicine, Cambridge
Benznidazole (BENZO) is a lipophilic analogue of
misonidazole which exhibits greater enhancement of
antitumour effects of the nitrosourea CCNU,
particularly when the sensitizers are compared at
low doses (Workman and Twentyman (1982), Br. J.
Cancer, 46, 249). Using BENZO doses which give
plasma concentrations which should be achievable
in man, we have evaluated the therapeutic gain for
its combination with CCNU using the KHT
tumour in C3H mice. The endpoints used were
regrowth delay for tumour, and LD50 and
depression of peripheral white cells for normal
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pharmacokinetics, using HPLC assay of BENZO,
CCNU and their metabolites.
Using a single dose of 0.3mmolkg-1 of BENZO
(ip) 30min before CCNU (ip) the dose modification
factor (DMF) for tumour response was 1.5-2.0
compared with 1.2-1.3 for white cells and LD50,
thus demonstrating a therapeutic gain for the
combination. For this dose the peak plasma and
tumour concentrations were about 0.1 mM and the
elimination tq about 2h. In experiments where
plasma concentrations of 0.1 mM were maintained
for 16h the tumour DMF was no greater than with
the single dose. BENZO increased the exposure to
CCNU by a factor of 2. Thus, as for misonidazole,
the chemosensitization mechanism involves changes
in CCNU pharmacokinetics (Lee and Workman,
these proceedings). The BENZO ti was 4-5h in
sheep (iv) and 6-12h in dogs (iv or ip). Plasma and
tumour concentrations of 0.1 mM were readily
obtainable. Tumour/plasma ratios of 50-100% were
seen in transplantable mouse tumours and
spontaneous dog tumours. As a result of these
promising chemosensitization and pharmacokinetic
data a Phase I clinical trial of BENZO plus CCNU
is now in progress.
Conjugation of methotrexate to antibody via an
albumin carrier confers selective cytotoxicity in vitro
M.C. Garnett, M.J. Embleton, E. Jacobs and R.W.
Baldwin
Cancer Research Campaign Laboratories, University
ofNottingham, Nottingham HG7 2RD
Methotrexate (MTX) was linked using stable
covalent bonds to a monoclonal antibody
(a79IT/36) against an osteogenic sarcoma cell line
via Human Serum Albumin (HSA) to obtain a
conjugate with a high molar ratio of drug to
antibody and specificity of action.
A conjugate of empirical formula
(MTX32-HSA)1 -3-x791T/36 was synthesised
which retained 25% of the original antibody
binding activity. The effectiveness of the conjugate
in vitro was- assessed against target cells of
previously determined reactivity towards a791T/36
using inhibition of 75Se-Selenomethionine uptake
as a measure of cytotoxicity. In a chronic 24h
exposure of drug to target cells, methotrexate
substituted HSA was 120-360 fold less toxic than
free methotrexate. The complete conjugate was as
toxic as free methotrexate against reactive target
cells but 40-fold less cytotoxic against non-reactive
target cells. In a competition cytotoxicity test
against free antibody, the cytotoxicity was shown to
be dependent on antibody binding. A further
variation of the cytotoxicity test in which conjugate
of free drug was incubated with target cells for
fifteen minutes followed by washing to remove
unbound material demonstrated that the conjugate
was capable of killing reactive but not non-reactive
target cells under these conditions. Although the
conjugate was 7-30 fold more active than free
methotrexate under these conditions, this was at
higher concentrations than in the chronic assay.
hnmunohistochemical localisation of milk fat globule
antigens in routine breast biopsy material
N. Berry, D.B. Jones, N. Kirkham, J. Smallwood,
I. Taylor & J. Taylor-Papadimitriou
Departments of Pathology & Surgery, Southampton
General Hospital and Imperial Cancer Research
Fund
Two monoclonal antibodies, HMFG-1 (1.10.F3)
and HMFG-2 (3.14.A4), identify antigens of the
human mammary milk fat globule and stain breast
biopsy tissue (Papadimitriou et al. (1981), Int. J.
Cancer, 28, 17; 21). An indirect immunoperoxidase
staining technique has been used to determine the
distribution of HMFG-1 and HMFG-2 antigen in
formalin fixed, paraffin embedded sections of breast
from 50 females. Nine of the specimens were
histologically normal. In these, HMFG-1 and
HMFG-2 stained both secreted material within, and
the luminal surface of cells lining many of the ducts
and tubules. Intracellular staining was occasionally
seen in these cells. HMFG-2 staining was stronger
than HMFG-1. Six cases of benign breast disease
showed the same staining pattern as normal breast.
Thirty-five cases of breast carcinoma were also
stained, comprising 29 ductal, 2 lobular, 2 mixed
ductal and lobular, 1 medullary and 1 carcinoid.
The staining pattern of the carcinomas varied and
could be crudely related to Bloom's grade (Bloom,
H.J.G. and Richardson, W.W. (1957), Br. J.
Cancer, 11, 359). Tumours showing much tubule
formation gave a staining pattern resembling that
observed in normal breast. Tumours with little
tubule formation showed either focal or diffuse
intracellular staining patterns. The pattern of
staining with HMFG-1 and HMFG-2 was the same
in all sections although HMFG-2 was generally
stronger than in HMFG-1. In 2 cases HMFG-1
stained tissue not stained by HMFG-2. The one
carcinoid stained with neither antibody staining
did not correlate with histological type of tumour124 PROCEEDINGS OF BACR 24TH AGM
but may relate to oestrogen receptor status. The
staining of cells isolated from fresh breast tumour
tissue has also been studied using these antibodies
in relation to the staining pattern of the original
tumour biopsy tissue.
Abdomino-pelvic C.T. scanning in the management of
carcinoma of the ovary. A possible alternative to
second look laparotomy
G. Blackledge, R. Johnson, B. Eddleston & D.
Crowther
Queen Elizabeth Hospital Birmingham, Christie
Hospital Manchester
121 CT scans were obtained in 75 women with
ovarian cancer; 108 of these were of the abdomen
and pelvis and 13 of the pelvis only. In 48 cases
pelvic CT was performed within 3 weeks of surgery
confirming the operative findings in all but 6. In
the abdomen, CT identified intra-hepatic deposits
and minimal ascites not seen at surgery; further
small peritoneal deposits (<1.5cm) were found at
surgery but not seen by CT. CT was superior to
clinical examination in all instances and was
undoubtedly helpful in assessing the feasibility of a
successful repeat laparotomy. More recently studies
suggest that unless second look laparotomy can
debulk residual tumour its function is limited. CT
scanning may be able to replace laparatomy in the
assessment of disease post chemotherapy and
minimise the number of patients requiring further
surgery.
Gallium scanning by conventional imaging (Ga-C)
and emission computed tomography (Ga-ECAT) in
the pretreatment evaluation oflung cancer
D.L. Broughton', R.C.F. Leonard2, T. Crake1, C.J.
Gibson1, S.J. Pearce'
'Department of Medicine and Regional Medical
Physics, Dryburn Hospital, Durham and
2Department of Clinical Oncology, University of
Edinburgh
In a prospective, coded study the clinical utility of
gallium imaging was assessed in 31 consecutive
patients presenting with radiological (CXR)
evidence of lung cancer. The study assessed (1) the
sensitivity of Ga-C and Ga-ECAT imaging in
relation to the location and histopathology (HPG)
of the tumour, and (2) the value of Ga-C and Ga-
ECAT in detecting mediastinal disease. Following
bronchoscopy (B) imaging was performed 72 hours
after a dose of 160 MBq of gallium citrate. ECAT
images were interpreted from both rotating pictures
and slice sections. The results showed (1) Gallium
imaging was accurate in all HPG subgroups (16
squamous, 6 adeno, 3 large cell, 3 small cell, 3
unclassified). Only one adenocarcinoma did not
show a clear primary. (2) Site of the primary on
gallium imaging correlated accurately with the
radiographic findings and there was no clear
variation of intensity of image with size and
location. (3) The mediastinum was more often
abnormal on Ga-C than CXR, B or ECAT. Twelve
patients had thoracotomy, ten had normal
mediastinal biopsies (M-) of whom two had been
equivocal (ME) on CXR. All were Ga-C M-. Two
patients had positive mediastinal node biopsies
(M+) who were M- ME on CXR but ME, M+
on Ga-C. Both were M- on Ga-ECAT. (4) In 13
non-surgical patients with a high probability of
M+ (B.M+ and/or CXR M+) 12 had Ga-C M+,
one ME; 10 had Ga-ECAT M+. In 6 with a low
probability of M+ (both B.M- and CXR M-)
Ga-C and Ga-ECAT gave discordant results. It is
concluded that Ga-C is accurate in detecting
mediastinal disease but Ga-ECAT imaging is not as
accurate and not a useful adjuvant to gallium
imaging. Ga-C is a valuable staging procedure in
the pretreatment assessment oflung cancer.
Does a factor in cancer sera change oxygen
utilisation of peripheral blood lymphocytes?
A.G. Paterson, A.D. Grimshaw & D.J.T. Webster
University Department of Surgery, Welsh National
School ofMedicine, Heath Park, Cardiff
We previously reported that lymphocytes from
patients with cancer have an increased consumption
of oxygen. We have now attempted to define
whether this observation is due to an intrinsic
function of the lymphocyte or due to a factor
present in serum of such patients. The results are
shown in the table. Papain causes levels of oxygen
consumption to return to normal when incubated
at 37°C but has no effect at 4°C.
Control (9)
Breast cancer
(10)
GI cancer (9)
After
Lymphocyte °2 incubation
consumption papain 370C
6.45+0.65 5.46+ 1.52
After
incubation
papain 4°C
6.31 +0.67
9.48+ 1.79 6.41+ 1.36 10.54±2.65
9.80+2.3 6.38+ 1.32 9.67+ 1.95
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When normal lymphocytes are incubated with
serum from patients with cancer oxygen
consumption in 9 patients rose from 6.34+0.90 to
9.65+ 1.67. No change was recorded in oxygen
consumption when serum from patients with
normal levels of oxygen consumption were
incubated with these lymphocytes.
These results suggest that the cause of increased
oxygen utilisation by lymphocytes from patients
with cancer relates to a serum factor rather than
being an intrinsic function of the lymphocytes.
Intratumour heterogeneity of thymidine labelling
index in primary breast cancer: The reason for its
failure as a prognostic indicator
M. Lambert
Department ofSurgery, University Hospital ofSouth
Manchester, Manchester 20
Tritiated Thymidine Labelling Indices (LIs) have
been determined from specimens of 22 primary
human breast cancers, using the hyperbaric in vitro
method of Meyer and Bauer (1975). Each fresh
specimen, typically measuring 2 x 2 x 4mm, was cut
crudely into 0.5mm thick slices, which were
incubated, processed and counted separately. An LI
was determined for each. A total of 2000-2500
tumour cells was counted in each microscopic
section in order to determine the LI. Repeated
counts upon each microscope slide showed that the
LI determined by this means was consistent, with
only one out of 22 repeat counts differing
significantly (P<0.05) from first count.
When the LIs of adjacent 0.5mm slices from
each specimen were compared, there was seen to be
a significant difference (P<0.05) in 19 out of 22
tumours, the significance:of the difference ranging
from P=0.05 to P=0.00001 (a four-fold difference
in LI) in these 19 pairs of adjacent slices.
Clearly there is great heterogeneity of
proliferative activity within a given primary breast
cancer. LI, or any other cell kinetic index based
upon evaluation of a single small sample in human
primary breast cancer is subject to considerable
sampling error and is unlikely therefore to be of
significant prognostic value.
The metastatic pattern of infiltrating lobular
carcinoma of the breast
M. Harris, A. Howell, M. Chrissohoou, M.J.
Hudson, R. Swindell & R.A. Sellwood
Departments of Pathology & Medical Oncology,
Christie Hospital, Department of Surgery,
Withington Hospital, Manchester, U.K.
We have compared the metastatic patterns of
infiltrating lobular carcinoma (ILC) and infiltrating
duct carcinoma (IDC) of the breast using both
clinical and autopsy data. Of 1082 patients with
breast cancer 135 (12%) had ILC and 831 (77%)
had IDC; 56 (41%) ILC's and 309 (37%) IDC's
were metastatic. In addition the post mortem
findings in 13 ILC's and 69 IDC's were compared.
The clinical data suggests that ILC is more likely
to produce metastases in the opposite breast (25%
vs 10%, P<0.004), in the leptomeninges (16%
vs 0.3%, P<0.0004) and diffuse bone marrow
involvement as judged by the proportion of positive
bone marrow trephines (72% vs 27%, P<0.0001).
At autopsy gastric (46% vs 3%, P<0.0001),
retroperitoneal (92% vs 9%, P<0.0001) and female
genital tract (38% vs 0%, P<0.0001) metastases
were significantly more frequent in ILC than IDC.
Seven of 12 ILC patients with retroperitoneal
spread had infiltration of the walls of the ureters
causing hydronephrosis; a feature not seen in IDC.
ILC is considered to have a distinctive metastatic
pattern compared with IDC.
A further analysis of mortality from cancer of the
prostate among nickel-cadmium battery workers by
the method of regression models in life-tables
T.M. Sorahan & J.A.H. Waterhouse
Cancer Epidemiology Research Unit, University of
Birmingham, B15 2TH
In a previous study of cancer morbidity among
men employed in the manufacture of nickel-
cadmium batteries (Kipling & Waterhouse, 1967), a
statistically significant excess of cancer of the
prostate was found (E=0.58, 0=4, P<0.01). The
present study updates and augments the original
series to a cohort of 2559 males employed in the
industry between 1923 and 1975 for at least one
month. The OPCS provided information on the
vital status of each individual on the closing date of
the survey, 31 January 1981. For those who had
died a death certificate was obtained with the126 PROCEEDINGS OF BACR 24TH AGM
underlying cause of death coded to the 8th revision
of ICD. Occupational histories were described in
terms of some 75 jobs: 8 with "high" and the
remainder with "moderate" or "minimal" exposure
to cadmium oxide (hydroxide). The method of
regression models in life-tables (RMLT) was used
to compare the estimated cadmium exposures
(duration of "high" exposure employment) of male
employees who died from cancer of the prostate
with those of matching survivors in the same year
of follow-up, whilst controlling for year and age at
commencing employment. A large test-statistic was
found but the relatively small number of deaths
upon which this statistic was based make the
estimation of a precise P-value difficult.
Simulations carried out would indicate, however,
that the statistic is significant at the 5% level. The
number of deaths available for analysis was
increased by considering those with cancer of the
prostate mentioned in Part I or Part II of the death
certificate. The effect of excluding the four
previously reported cases was to reduce the
significant positive statistic to a small non-
significant negative statistic. Thus no new evidence
has been provided which suggests an association
between occupational exposure to cadmium oxide
(hydroxide) dust and cancer of the prostate.
Nitrosamine exposure in the rubber industry
B. Spiegelhalder and R. Preussmann
Institute of Toxiciology and Chemotherapy, German
Cancer Research Center, Heidelberg
Recent investigations (Fajen, J.M. et al. (1979),
Science, 205, 1262) of nitrosamines in the rubber
industry indicate the widespread occurrence of
considerable levels of nitrosodimethylamine and
nitrosomorpholine.
In order to elucidate the origin and formation of
nitrosamines in this industry, chemicals as well as
the air in various areas were analyzed. All
chemicals used for rubber compounding contain
nitrosamines if they are derivatives of secondary
amines, e.g. tetramethylthiurame, zinc-
diethyldithiocarbamate or N-oxydiethylene
benzothiazolylsulfonamide. Accordingly, variable
concentrations of airborn nitrosamines could be
detected at places where rubber products are
manufactured or stored. The nitrosamines found
correspond to the compounded chemicals. The
original nitrosamine level in rubber chemicals is not
high enough to explain the amounts found in
rubber products and in air. Therefore additional
nitrosation had to be considered. The responsible
nitrosating agents are nitrogen oxides released from
rubber chemicals (e.g. nitrosodiphenylamine) or
from combustion gases. Preliminary results show
that in most cases either by elimination of the
nitrosating agent or by exchange or rubber
chemicals nitrosamine levels in the working area
can be drastically reduced.
Pharmacokinetic studies in humans with CB3717
(N-(4-(2-amino-4-hydroxy-quinazolinyl)methyl)
prop-2-ynylamino)benzoyl)-L-glutamic acid)
D.L. Alison, D.R. Newell & A.H. Calvert
Department of Biochemical Pharmacology, Institute
ofCancer Research, Sutton, Surrey
CB3717 is an antifolate acting by inhibition of
thymidylate synthetase which began early clinical
trials at The Royal Marsden Hospital in September
1981. Pharmacokinetic studies have been
undertaken in 11 patients following a 1 h infusion
of CB3717 and in 4 patients receiving a 12h
infusion at doses ranging between 100mgm-2-
500mgm 2. In 9 of these patients the decay of
drug levels in the plasma followed a biphasic
pattern with an average tqca of 69.7min (range
13.3-173.3min) and an average t-2Lc. of 556min
(range 228-1386min). Peak plasma levels were
linearly related to dose, falling within the range
previously found to be therapeutic and cytotoxic in
preclinical studies and the highest level recorded
was 60jgml1 (122.7jM). In patients receiving a
12h infusion of CB3717 at doses of 300mgm2,
and 330mgm-2 peak levels of the drug measured
8, 15.5 and 36jugml-1 (16.4, 31.7 and 73.61jM)
respectively and these were lower than the levels
achieved by the same dose given over 1 hour. The
mild reversible hepatic toxicity which occurs in
approximately 50% of patients, demonstrated by
rises in plasma transaminase levels, did not appear
to be related to the rate of drug infusion, dose
given or peak plasma level attained but did show
correlation with the rate of clearance of the drug.
24 hour urine collections following 45 drug
treatments showed the average urinary excretion of
CB3717 to be 25% (range 4-75%). In addition, an
incomplete faecal collection following a 5 day dose
regimen in one patient yielded 12% of the total
CB3717 given and some of the desglutamyl
metabolite CB3751. This metabolite has not been
detected in either plasma or urine samples and has
been shown to be non cytotoxic and inactive as a
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tissue samples have been analysed from one patient
who died 7 days after his second dose of CB3717 at
a dose of 330mgm-2 and - 5% of the dose given
was calculated to be present in the kidneys. Finally,
protein binding experiments have demonstrated
99% plasma protein binding of CB3717.
Evaluation of ECAT techniques for the measurement
of gallium-67 uptake in the chest
C.J. Gibson, R.C.F. Leonard' & J. Aikenhead
Regional Medical Physics Department and
'Department of Medicine, Dryburn Hospital,
Durham, DHI 5TW
The distribution of 67Ga-citrate uptake in patients
with bronchogenic carcinoma may be an indicator
of the extent of the disease, and therefore useful for
staging and management. Gallium uptake is non-
specific and is also used to detect foci of infection,
hence the volume of distribution of gallium may
represent inflammatory tissue as well as tumour.
However, the overall shape of the uptake gives
information about the three dimensional
distribution of disease. We investigated the
technique of emission computed axial tomography
(ECAT) for the determination of volume and shape
of gallium uptake. Irregular bags containing
concentrations of gallium representative of tumours
were imaged in an anthropomorphic chest
phantom. Using a rotating gamma camera, ECAT
images were obtained and the volume measured
from the reconstructed sections compared with the
known volume. We were able to show that
tomographic imaging was possible even with the
low concentrations used (0.02MBqmlP1), and that
accurate measurement of volume was possible for
volumes above 200ml. The use of a variable
threshold for defining small volumes improved the
accuracy, but required more complex data
processing. The technique has been applied to
clinical studies and examples are shown indicating
the ability of ECAT to display the three
dimensional distribution of gallium in lung cancer.
The recovery of tumour cells from colorectal tumours
and colonic lavage following centrifugation of cell
suspensions on nycodenz columns
H.C. Umpleby, B. Fermor, M.O. Symes & R.C.N.
Williamson
Department ofSurgery, University ofBristol
Cell suspensions were prepared from 9 colorectal
carcinomas by digestion in collagenase+DNase.
One ml of each cell suspension (3.0-28.5 x 106,
mean 16.2 x 106 cells) was placed on a separate
density gradient Nycodenz column. Nycodenz
(Nyegaard & Co., Oslo) was diluted with medium,
5mmoll 1- Tris HCI, 3mmoll-P KCI, 0.3mmoll-P
CaNa2 EDTA, 7.5g NaClI-1 distilled water. Each
column comprised 4, 3ml layers, Nycodenz,
Nycodenz diluted 2: 1 with medium, diluted 1:1
and diluted 1:2, in a conical centrifuge tube. Each
tube was placed in a horizontal position for 45min
at room temperature prior to application of the
tumour cell suspension. Each column was
centrifuged at 1500g for 45min at room
temperature. The cells obtained were localised in 4
bands ofwhich the top contained most ofthe tumour
cells. The % recovery of cells in this band was 0.8
to 22.5 (median 3.6) for the 9 colon tumours. With
4 of these tumours a count differentiating tumour
cells, mononuclear cells and dead cells was made on
a cell suspension diluted with 0.165%w/v trypan
blue using a haemocytometer. The % of tumour
cells was 82, 90, 95 and 100. Nineteen patients
received a colorectal lavage with 500ml of
Hartmans solution. The resulting cell suspension
was concentrated by centrifugation and applied to a
Nycodenz column. The top band contained a
median of 0.25 x lO6ml-l (range nil-100 x 106)
viable tumour cells-there being 5 cases from which
no tumour cells were recovered. In a further 18
patients the transected ends of the bowel were
washed with Medium 199 and the concentrated cell
suspension applied to Nycodenz column. Viable
tumour cells were recovered from 12 of 18 cases,
median 0.17 x 106ml-' range (nil-4.5 x 106).
Viability was confirmed by showing that the
tumour cells incorporated fluorescein.
Cytocentrifuge preparations demonstrated the
presence of tumour cells in the top band in 7 of 13
cases following lavage and 8 of 14 cases after
margin washing.
Patterns of acute phase reactant proteins (APR's)
and immune complexes (IC's) in lymphomas
compared with other systemic diseases
J.P. Pape, R.C.F. Leonard, S.J. Proctor, W.P. Carr,
M.S. Jeffery & W.C. Dick
Departments of Rheumatology, Clinical Oncology &
Medicine, University ofNewcastle upon Tyne
Recently interest has been revived in the
measurement of APR's in diseases characterised by
systemic illness. In non-Hodgkin's lymphoma
elevation of C-reactive protein (CRP) has been128 PROCEEDINGS OF BACR 24TH AGM
associated with poor prognosis. Generally, the
function of the APR's is far from clear, although
their evolutionary conservation implies an
important physiological action. We have attempted
to learn more about their possible functions by
examining patterns of APR's in lymphomas,
compared with normals and other inflammatory
diseases. A second common abnormality in the
chosen disease groups is the presence of circulating
immune complexes. It has been hypothesised that
individual APR's may be associated with IC's and
these have been correlated in our studies, along
with the complement factor C3. All APR's and C3
were measured by nephelometry.
The APR's examined were alpha-l-antitrypsin
(al-AT), alpha-l-acid glyco-protein (al-AGP),
alpha-2-macroglobulin (a2-M) and CRP.
The data shows that the CRP concentration in
lymphomas are elevated compared with controls
and differ from those of other disease groups.
However, preliminary analysis indicates no clear
correlation between the APR level and (1) clinical
stage (2) histopathology (3) treatment status.
Mechanisms of gastric distension following cytotoxic
drugs. Effects of metoclopramide
B. Jones & M.G. Stone
Richard Dimbleby Department of Cancer Research,
St. Thomas's Hospital Medical School, London SE]
7EH
Nausea and vomiting are important side effects of
cytotoxic chemotherapy. Laboratory experiments
involving emesis have necessarily been limited to
large animals. The following experiments were
performed using C3H mice in which severe gastric
distension, but not emesis, occurs after a variety of
cytotoxic drugs. The degree of distension was
assessed by measuring weights and volumes of
stomachs removed 24h after cytotoxic drug
administration. Marked distension occurred
following single LD50 doses of Neoplatin, CHIP (a
platinum IV complex); Cyclophosphamide and
lethal total body irradiation (15Gy). The effect did
not occur following Adriamycin or the platinum
containing drug FLAP (I000mgkg-1 p.o.).
Single doses of Metoclopramide (0.5, 5 or
25mgkg-1 i.p.) produced a small non-dose
dependent reduction in CHIP and
Cyclophosphamide-induced distension within 1h.
Multiple doses of Metoclopramide (5mgkg-1x6)
over the 24fh period did not yield any reduction in
distension. This implies that pyloric sphincter
closure is not responsible for distension. This is
supported by finding no reduction in transit of
small carbon beads (0.25-0.60mm) between the
oesophagus and the appendix in CHIP treated
mice. Starvation effectively reduced the degree of
distension by 73%.
This model suggests that the clinical benefits of
high dose Metoclopramide following platinum
drugs are due to central rather than direct gastric
effects.
Genetic damage initiated in somatic cells by oxygen-
derived radicals produced by normal metabolic
reactions
B.J. Phillips and T.E.B. James
British Industrial Biological Research Association,
Carshalton, Surrey
Oxygen-derived radicals have been implicated in the
mechanisms of action of ionizing radiation, some
chemical carcinogens and tumour promoters, and
certain anti-cancer agents. Oxygen radicals are
produced by many normal cellular enzymes and are
released by phagocytic cells in response to foreign
substances. It has been suggested that under
abnormal circumstances these physiological sources
of radicals could cause or promote carcinogenesis.
Cultured Chinese hamster ovary (CHO) cells were
incubated with either xanthine plus xanthine
oxidase or guinea-pig alveolar marcophages
stimulated by various means. In both systems the
generation of superoxide radicals was
demonstrated. Severe chromosome breakage and
sister chromatid exchange (SCE) were observed
after exposure to conditions of high superoxide
production. Chromosome breakage was abolished
by superoxide dismutase (SOD) or catalase (CAT)
implying that both superoxide and hydrogen
peroxide were necessary for this effect. SCE was
prevented only by catalase. The chromosomal
effects studied are considered to be indicative of
genetic damage which might underlie
carcinogenesis.
Promotion of N-nitrosodimethylamine-initiated bile
duct carcinogenesis in the hamster by the human liver
fluke Opisthorchis viverrini
D.J. Flavel & S.B. Lucas
Department of Medical Helminthology, London
School of Hygiene & Tropical Medicine and
Department of Histopathology, St. Thomas'
Hospital, London
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million human beings in the north-east of Thailand
(Wykoff et al. (1965), J. Parasitol., 51, 207) and
appears to be an aetiological factor in the causation
of bile duct carcinoma (Flavell (1981), Trans. Roy.
Soc. Trop. Med. Hyg., 75, 814). In order to test the
hypothesis that this parasite might act as a
promoter of bile duct carcinogenesis, initiated by an
exogenous carcinogenic agent, the following
experimental groups of hamsters were set up.
Group I animals received 50 0. viverrini
metacercariae followed 41 days later (when biliary
hyperplasia was well established) by 1.6mg N-
nitrosodimethylamine (NDMA), Group II received
1.6mg NDMA followed 96h later by 50 0. viverrini
metacercariae, Group III received 1.6mg NDMA
only and Group IV 50 0. viverrini metacercariae
only. Animals were left until natural death or were
sacrificed when moribund and full post mortems
performed. A total of five (10%) animals from
Group I and nine (20%) from Group II developed
intrahepatic bile duct carcinoma. None of the
animals from Groups III and IV developed
malignant bile duct tumours, though benign cystic
cholangiomas were found in the majority of
animals from Group III. These results show quite
clearly that the parasite-mediated biliary epithelial
cell proliferation is not a prerequisite during the
NDMA-initiation phase of carcinogenesis. To the
contrary, a higher tumour yield was obtained in
animals initiated with NDMA before receiving
parasites. These results therefore strongly suggest
that the liver fluke, Opisthorchis viverrini acts as a
promoter of NDMA-initiated bile duct
carcinogenesis in the hamster, providing a model
two- (or multi-) stage carcinogenesis system with
some direct relevance to a malignancy of man.
A multistage hypothesis for NDMA-initiated bile
duct carcinogenesis in Opisthorchis viverrini infected
hamsters
D.J. Flavell
Department of Medical Helminthology, London
School of Hygiene & Tropical Medicine, Winches
Farm Field Station, St. Albans AL4 OXQ
A multistage hypothesis implicating the liver fluke,
Opisthorchis viverrini as both a direct and indirect
promoter of NDMA-initiated bile duct
carcinogenesis is presented here.
1. Initiation with a subcarcinogenic dose of
NDMA produces latent tumour cells of biliary
epithelial origin.
2. The parasite predisposes the human (Teoh
(1963), J. Path. Bact., 86, 123) and hamster
(Flavell, unpublished observation) hosts to
colonisation of the biliary tree with species of
gut microflora (pyogenic cholangitis). The
presence of certain species of gut bacteria might
result in the conversion of primary to secondary
bile acids, the latter being established promoters
of carcinogenesis (Reddy et al. (1978),
Carcinogenesis: A Comprehensive Survey, Raven
Press. pp. 453-464).
3. The parasites located in the intrahepatic bile
ducts abrade and damage the mucosal lining of
the duct wall (Flavell et al. (1980), Acta Tropica,
37, 337) thus allowing for easier access of bile
borne components to the membrane surface of
the biliary epithelial cell which is subsequently
promoted by secondary bile acids.
4. The growth of foci of NDMA-initiated and
secondary bile acid promoted progenitor tumour
cells is further accelerated through the
proliferative stimulus exerted on the biliary
epithelium by the parasite.
Alkylation ofhepatic Haem by diethylnitrosamine:
Formation of N-hydroxyethyl protoporphyrin IX
I.N.H. White, A.G. Smith & P.B. Farmer
Toxicology Unit, MRC Laboratories,
Woodmansterne Road, Carshalton, Surrey
Mice dosed with diethylnitrosamine form an
abnormal green pigment in their livers. A procedure
based on HPLC was used to separate and
quantitate this product. Formation of green
pigment was time and dose dependent and was
induced by pretreatment of mice with either
phenobarbitone or 3-methylcholanthrene.
The aetio-type absorption spectrum of the
purified green pigment dimethyl ester suggested it
to be a N-alkylated porphyrin. Desorption chemical
ionisation mass spectrometry gave a protonated
molecular ion m/z=635, compatible with N-
hydroxyethyl protoporphyrin IX. No conversion of
N-ethyl protoporphyrin IX to N-hydroxyethyl
protoporphyrin IX could be demonstrated in vivo
or in microsomal systems in vitro. A reaction
mechanism is proposed involving an initial f-
hydroxylation of one ethyl substituent of
diethylnitrosamine followed by the formation of a
,B-hydroxyethyl carbonium ion. The alkylation of
other cellular macromolecules such as DNA by the
proposed metabolite is being investigated.130 PROCEEDINGS OF BACR 24TH AGM
Activity of 06-methylguanine-DNA repair protein in
animal tissues in relation to their susceptibility to
cancer induction by alkyl-nitroso-ureas
V.M. Craddock
MRC Toxicology Unit, Woodmansterne Road,
Carshalton, Surrey
Much evidence suggests that initiation of cancer
depends on replication of DNA containing
carcinogen-derived adducts, i.e. it depends not only
on the extent of the initial reaction of carcinogen
with DNA but also on the rate of cell replication
and on the persistence and therefore on the rate of
repair of the relevant lesions. Measurement of
repair capacity in vivo is difficult owing to dilution
of the damaged DNA by nascent DNA, saturation
of the repair system by a high dose of carcinogen,
biphasic removal of adducts etc. A rapid simple
method has recently been developed (Craddock et
al. (1982), Biochim. Biophys. Res. Comm., 107, 546)
for determining the ability of tissue extracts to
remove the methyl group from O6MB-DNA. This
method has been used to assess the importance of
repair in carcinogenesis by comparing repair ability
and rate of cell replication in animal tissues which
have very different susceptibilities to cancer
induction by a low dose of NMU, i.e. rat and
mouse liver, spleen, thymus, lung and brain. As
susceptibility in the rate varies very markedly with
age, the repair capacity of rat liver and brain at
different stages of foetal and post-natal
development has been measured. The results
support the view that it is essential to consider the
effect of the carcinogen on cell replication
as well as the extent and persistence of O6MG in
DNA.
Quantitation of 06-methyldeoxyguanosine and 02_
methylthymidine in cellular DNA using monoclonal
antibodies
C.P. Wild, R. Saffhill & J.M. Boyle
Paterson Laboratories, Christie Hospital and Holt
Radium Institute, Manchester M20 9BX, U.K.
Mouse hybridomas producing monoclonal
antibodies to the putative promutagenic lesion 0C6_
methyldeoxyguanosine 06-MedG) and 02_
methylthymidine (02-MedT) have been
characterised by radioimmune assays (RIA). In
competitive RIA, 50% inhibition of binding of anti-
06-MedG and anti-02-MedT to the respective [3H]-
antigens was obtained using 0.3pmol of cold 0o6-
MedG and 0.5pmol of 02-MedT respectively.
Similar assays using normal nucleotides and the
major methylation product, N-7 methylguanine in
tests of cross reactivity showed that > 106 and
> 105 higher concentrations of these compounds
were required to cause the same inhibition of
binding of anti-06-MedG and anti-02-MedT. The
06-MedG and 02-MedT antibodies have affinity
constants of 3 x lO91mol-1.
A technique has been developed which allows 5-
25 ug clean DNA to be obtained from 1-5 x106
cells by extraction on polycarbonate filters. The
DNA can be completely enzyme hydrolysed and the
nucleosides separated by Aminex A6
chromatography thus allowing the
spectrophotometric quantitation of normal
nucleosides and RIA of the alkylated nucleosides.
Using this technique we have determined the
percentage of 06-MedG removed in 24h by
fibroblasts of human lung tumours, MRC-5 (60%),
and Chinese hamster cell lines, V79A2 (10%) and
V79/79 (55%) using doses of N-methyl-N-
nitrosourea as low as 0.5mM.
DNA repair enzymes in human cell lines sensitive
(Mex-) and resistant (Mex+) to nitrosoureas
A.L. Harris', P. Karran, B. Demple & T. Lindahl
'CRC Unit, Royal Victoria Infirmary, Newcastle
upon Tyne and ICRF, Mill Hill, London
Human cell lines differ in their rate of removal of a
specific alkylation lesion from DNA-C)6 methyl
guanine (O6MeG) (Sklar and Strauss (1981),
Nature, 289). Mex- cell lines (slow removal rate)
are more sensitive to methyl nitrosourea (MNU),
CCNU and BCNU than Mex+ cell lines. In E. Coli
exposure to MNU induces a specific suicide
enzyme, 06 MeG transferase (O6MeGt), that
removes the methyl group from O6MeG, leaving
the base intact. We have detected a similar enzyme
in human cell lines, measured its activity in 2 mex+
and 2 mex- cell lines and the activity of 4
glycosylases. Enzymes were extracted from 1-5 g of
cells and partially purified by AcA54
chromatography. O6MeGt activity was measured
after acid hydrolysis and HPLC of [3H] MNU
alkylated DNA substrate. 3Me guanine, 3Me
adenine and 7Me guanine glycosylase were
measured by HPLC of supernatants after
incubation with [3H] DMS labelled DNA. Uracil
glycosylase was measured by counting uracil (U)
released from [3H]U DNA.PROCEEDINGS OF BACR 24TH AGM 131
No O6MeGt was detectable in mex- cell lines,
even after partial purification. Both mex+ cell lines
had similar levels of O6MeGt. Thus, mex- cell lines
have at least 100 x less enzyme than mex+. Mixing
experiments showed no evidence of inhibitors.
There was no difference in glycosylases in the 4 cell
lines (Raji, GM1953, GM621, GM829). These
results show lack of a specific enzyme is correlated
with sensitivity to nitrosoureas. These enzyme
assays will be applied to samples from human
tumours in patients treated with nitrosoureas.
Metabolism and carcinogenicity of alkylated
polycycic hydrocarbons
M.R. Osborne and P. Brookes
Institute ofCancer Research, London, U.K.
We have examined the metabolism by rat liver
microsomes of a number of carcinogenic and non-
carcinogenic polycyclic hydrocarbons, in order to
determine how alkyl-groups affect the metabolism
and carcinogenic potency; all 12
monomethylbenzanthracenes and 6 alkylated
benzopyrenes. The presence of an alkyl-group
affected metabolism not only at the bond to which
it was attached, but also at neighbouring sites. For
example, metabolism at the K-region (5,6-) of
benzanthracene was inhibited by methyl-groups at
the 4-, 5-, 6- or 8-positions. The carcinogenic
potency of the hydrocarbons could only partly be
explained in terms of their pattern of metabolism.
Some methylbenzanthracenes were capable of
yielding 3, 4-dihydrodiols, but were not
carcinogenic; 1-isopropylbenzo(a)pyrene could be
metabolised on the 7, 8, 9, 10-ring but was also
inactive. The diolepoxides derived from these
hydrocarbons are probably unreactive owing to
electronic and steric factors, respectively.
Variance in resistance to NK cell-mediated lysis
among K562 lines: Influence of sodium n-butyrate on
sensitivity
I. Kimber & M. Moore
Department of Immunology, Paterson Laboratories,
Christie Hospital and Holt Radium Institute,
Manchester M20 9BX
Mammalian natural killer (NK) cells have the
capacity to bind to, and lyse, a variety ofmalignant
and non-malignant cells in short term culture.
Although the nature of the effector cells has been
extensively studied the characteristics which
determine resistance or susceptibility to NK-
mediated lysis remain unclear.
To facilitate investigation of the factors which
predispose cells to lysis we have isolated sub-
populations of the erythroleukaemic cell line K562
by limiting dilution techniques. The characteristics
of two such sub-lines, El0/P2 and F9/P2, which
differ markedly in their susceptibility to NK cells
have been examined in detail. We have
demonstrated that such differences are not
attributable to the level of expression of NK cell
receptor sites and are probably secondary variable
membrane repair capacity following immunological
lesions.
We report that treatment of the resistant line
(F9/P2) with the differentiating agent sodium n-
butyrate induces a significant increase in lytic
sensitivity within 48 hours, which is apparently
independent of enhanced NK cell receptor
expression. Similar treatment of the sensitive line
(EIO/P2) fails to increase susceptibility. These data
suggest that the sensititivity of target cells to
immune lysis is influenced by their level of
differentiation.
Tumour growth inhibitory activity of short term in
vitro cultured lymph node cells (LNC) derived from
mice pre-treated with or bearing a non-immunogenic
tumour
K.D. Chandradasa & J. Blears
Department of Immunology, University of Liverpool,
P.O. Box 147, Liverpool L69 3BX
Tumour inhibitory activity was detected in short
term cultured LNC from mice bearing a "non-
immunogenic", naturally arisen tumour-SP/N-1
(Chandradasa & Blears (1982a), Eur. J. Cancer and
Clin. Oncol., 18, 1063; (1982b), 853). We
investigated this phenomenon further in a different
naturally arisen Balb/c tumour-SP/T-l, which also
failed to elicit a detectable antitumour response in
the isogenic host. Tumour pre-treated mice failed to
suppress (104 tumour cells) a cell dose that forms
tumour in nearly 100% of the inoculated animals,
when tested by tumour challenge as well as by cell
transfer assays. When LNC from mice repeatedly
inoculated with Mitomycin C (MMC) treated
tumour cells were cultured in vitro for 45h, the
resulting cells acquired the ability to suppress the
tumour outgrowth in cell transfer assays, quite in132 PROCEEDINGS OF BACR 24TH AGM
contrast to the ineffectiveness of non-cultured LNC
from similarly pre-treated donors. Cultured LNC
obtained from tumour-bearers were also inhibitory
although less so than those obtained from tumour
pre-treated animals. Non-cultured cells obtained
from normal, tumour bearing or tumour pre-
treated animals as well as cultured normal LNC
failed to show tumour inhibitory activity. These
observations indicate that in vivo suppression of
effector cell differentiation may be the reason for
"non-immunogenicity" of the tumour systems we
have investigated.
Preliminary investigating on the mode of action of
CCRG 81010 (M&B 39565)
C. Horgan, M.F.G. Stevens & M.J. Tisdale
CRC Experimental Chemotherapy Group,
Department of Pharmacy, University of Aston in
Birmingham, B4 7ET, U.K.
The new antitumour drug CCRG 81010 (or M&B
39565) is an unstable molecule which can
potentially liberate a cascade of reactive and
cytotoxic species in vivo. Two obvious degradation
pathways could be expected: (i) formation of 2-
chloroethylisocyanate and 5-diazoimidazole-4-
carboxamide and (ii) ring-opening leading to
formation of 5-[3-(2-chloroethyl)triazen-1-
yl]imidazole-4-carboxamide (MCTIC).
Recent results (Gibson & Hickman (1982),
Biochem. Pharmacol. 31, 2795) have suggested that
the TLX5 lymphoma cells may be sensitive to
BCNU in vivo as a consequence of the intracellular
release of 2-chloroethylisocyanate. On the other
hand chloroethylnitrosoureas are generally
considered to exert their activity (against L1210) via
the alkylation and cross-linking of DNA. We were
interested to examine the in vitro effects of CCRG
81010 in comparison with BCNU and MCTIC in
the hope that they might shed light on the mode of
action of the new drug. Under conditions where
BCNU produced a marked inhibition of
glutathione reductase in TLX5 lymphoma cells
CCRG 81010 was without effect. Similarly CCRG
81010 proved to have no effect against y-
glutamyltranspeptidase and a-chymotrypsin in
direct drug-enzyme inhibition studies. BCNU
caused a large decrease in incorporation of (methyl-
3H) thymidine and (5-3H) uridine into acid-
precipitable material in TLX5 cells in vitro, but an
equi-cytotoxic concentration of CCRG 81010 had
little early effect. The biochemical evidence suggests
that 2-chloroethylisocyanate release is not an
important factor in the mode of action of CCRG
81010 and the parameters investigated thus far
point to its having similar mechanism of action to
MCTIC.
Uptake and retention of cis-platin and cis-diammine-
1,1-cyclobutane dicarboxylate platinum II (CBDCA,
JM8) in rat erythrocytes
Z.H. Siddik, D.R. Newell, F.E. Boxall, K.G.
McGhee & K.R. Harrap
Dept. Biochemical Pharmacology, Inst. Cancer Res.,
Sutton, Surrey, England
In rats, death from cis-platin is usually ascribed to
either renal failure, gastrointenstinal toxicity or
both. As yet, evidence of pathological lesions which
would afford a plausible explanation for CBDCA-
induced lethalities is lacking. Recent studies in our
laboratory indicate that toxicity to the erythrocytes
by CBDCA may provide an explanation for the
lethal event. Intravenous administration of CBDCA
(80mgkg-1) to rats results in a 70% decline in the
erythrocyte count by day 9, and death ensues a
day later. In contrast, lethalities from cis-platin
(10mgkg-1) are preceded by haemoconcentration.
Atomic absorption spectrophotometric analyses of
whole blood and plasma demonstrated that in
animals receiving CBDCA, the Pt concentration in
the erythrocytes is twice that seen in rats given cis-
platin. Similarly, whole blood-plasma Pt ratios 4
days after administration were about three-fold
greater for CBDCA than cis-platin (14 vs. 4). Taken
together, these results indicate that the
accumulation of Pt in the erythrocytes of rats
treated with CBDCA is significantly greater than in
animals given cis-platin. Parallel studies in vitro
with rat whole blood resulted in similar findings,
with cis-platin (30juM) and CBDCA (3001uM)
giving erythrocyte/plasma Pt ratios at 24h post
incubation of 1.5 and 3.4 respectively. The greater
intracellular accumulation of Pt from CBDCA
appears to be due to its faster rate of irreversible
binding in the erythrocyte than in the plasma.
These results are consistent with the premise that
deaths from CBDCA may be associated with
erythrocyte toxicity.PROCEEDINGS OF BACR 24TH AGM 133
Modulation of the acceptance of transfer RNA for
amino acids by alkyl aryltriazines and imidazoles
G.F. Kolar & J. Hradec
Institute for Toxicology and Chemotherapy, German
Cancer Research Centere, Heidelberg, F.R.G.;
Department of Biochemistry, Oncological Institute,
Prague, Czechoslovakia
Selected triazenes and imidazoles were incubated
with postmitochondrial supernatants from rat liver,
and tRNA isolated therefrom was charged with 13
different amino acids. The majority of tested
compounds enhanced the acceptance of initiator
tRNA but inhibited the formation of L-leucyl-
tRNA. The direct alkylating monomethyltriazenes
enhanced the acceptance of initiator tRNA when
incubated alone with unfractionated tRNA whereas
the procarcinogenic dialkyltriazenes showed this
effect only after preincubation with
postmitochondrial supernatant containing the
activating enzymes. It appears that the reactive
molecular species [CH3-N_N+,
CH3-N=N-OH], that arise from
monomethyltriazenes by heterolysis, or from
dimethyltriazenes by enzymic activation, modify the
structure of tRNA in a specific manner, possibly by
methylation. These results are in complete
agreement with previous experience with
carcinogenic and noncarcinogenic polycyclic
hydrocarbons and azo dyes. Moreover, they
provide additional supporting evidence that the
enhanced acceptance of initiator tRNA seems to be
indicative for the generation of electrophilic
(potentially carcinogenic) intermediates from the
incubated compounds.
In vivo metabolism of adriamycin in the rat:
Identification of new metabolites
J. Cummings', N. Wilmott2, J.F.B. Stuart" 2 &
K.C. Calman'
'Department of Clinical Oncology, University of
Glasgow, Glasgow and 2Department of
Pharmaceutics, University ofStrathclyde, Glasgow
As part of a continuing study of adriamycin (ADR)
metabolism in different tissues, with regard to
cardiac toxicity and anti-tumour effect, we have
examined in vivo metabolism of the drug in selected
rat tissue. Previous reports of the disposition of
ADR by this species have found little evidence for
its biotransformation. In this present work rats
were given ADR 10mgkg-' i.v. and then killed
sequentially with time. Blood, heart, lungs, liver,
kidneys and a subcutaneously growing Mc 40A
tumour were collected; the tissues and tumour were
immediately frozen in solid CO2 and all were stored
at -20°C ready for analysis. ADR and its
metabolites were extracted from homogenised
tissues and blood with chloroform: isopropanol
(2:1) by a new method which uses a Buchler
Vortex Evaporator. Extracts were analysed by high
pressure liquid chromatography (HPLC) and thin
layer chromatography (TLC). Kinetic behaviour of
ADR and metabolite profiles varied from tissue to
tissue. For example in liver ADR and 3 metabolites
which accounted for >50% of the ADR were
eliminated very rapidly in an almost identical
fashion to the plasma. Whereas in the tumour the
ADR level peaked after four hours and fell very
slowly, only one metabolite was detected and this
was present in only very small amounts. Two
metabolites previously reported not to be present in
the rat were identified by chromatographic mobility
to be adriamycinol 7-deoxy-aglycone and
adriamycin 7-deoxyglycone. These in vivo products
were isolated from the tissue extracts using 1 mm
preparative TLC plates, their chemical identity
established by rechromatographing against pure
standards and verified by mass spectroscopy. The
new data is clear evidence for extensive metabolism
of ADR by the rat. Qualitatively the pathways of
metabolism are the same as other species examined,
including man, although quantitative differences
exist.
Increased thymidylate synthetase activity in L1210
cells resistant to CB3717
A.L. Jackman, D.L. Alison, A.H. Calvert & K.R.
Harrap
Department of Biochemical Pharmacology, Institute
ofCancer Research, Sutton, Surrey
Defining mechanisms of resistance to an
antimetabolite may be of use in the elucidation of
its locus of action and may allow the development
of improved analogues which are not cross-
resistant. In addition, if resistance is due to over
production of the target enzyme then it should be
possible to purify large quantities of the enzyme for
a number of studies such as sequencing the primary
structure and affinity-labelling the active site.
Thymidylate synthetase (TS) is the rate-limiting
enzyme in the de novo synthesis of thymidylate. In
the absence of salvageable thymidine a cell is
completely dependent on its de novo thymidylate134 PROCEEDINGS OF BACR 24TH AGM
pathway for DNA synthesis. Cytotoxicity of the
pyrimidine analogues 5-fluorouracil and 5-
fluorodeoxyuridine requires the presence of the
activating enzymes phosphoribosyl transferase and
thymidine kinase respectively, and resistance is
frequently determined by deletion of these enzymes
and not by an increase in the target enzyme TS. A
small increase in TS (6-10 fold) has been achieved
in a hepatoma cell line although resistance was lost
in the absence of drug (Priest et al. (1980),
Biochem. Pharm., 29, 1549-1553). CB3717 is a
quinazoline analogue of folic acid whose sole
cytotoxic locus is TS (Ki=4nM) and which does
not require metabolic activation. In the present
communication resistance to CB3717 in L1210 cells
was raised by passaging cells in a culture medium
containing negligible amounts of salvageable
thymidine, with incremental concentrations of the
drug. Resistance was slow to develop initially but
eventually the cells became completely resistant to
500,uM CB3717 (ID50 for sensitive line=5jiM).
Several monoclonal lines have been isolated and all
share the common feature of raised TS (- 30 fold).
The mutation appears to be stable in the absence of
CB3717 (>6 months). There is no cross-resistance
to 5-fluorouracil, 5-fluorodeoxyuridine or
methotrexate. We have purified TS from one of the
resistant cell lines by affinity chromatography and
have shown that the kinetic constants and
inhibition by CB3717 is the same as that for the
sensitive line. This suggests that the gene product is
identical. Future work will show whether gene
amplification is the mechanism of resistance.
Melphalan+
Melphalan Prednisolone
WBC WBC
Rat LD50* nadirt LD50* nadirt
Male 3.7+ 1.4 25% 5.7 20%
Male tumour
bearing 11.3 N.D. 3.2+0.9 N.D.
Female 10.1 50% 5.6 23%
*mgkg-1 melphalan i.v.+95% confidence limits where
available.
tEffect of2mgkg- melphalan i.v. as % control.
N.D.-not determined.
In female rats and in tumour-bearing male rats the
increase in M toxicity produced by P was maximal
when the two drugs were administered
simultaneously. Furthermore, the P-induced
increases in M (4mgkg-1 i.v.) haematological and
gastrointestinal toxicity were dose-dependent over
the range 0.1-100mgkg-1 P. As combinations of
M and P were no more effective than M alone
against the Walker 256 carcinosarcoma the
therapeutic index of M was reduced by its
combination with P. Hence against human disease,
if the combination of M and P is not more effective
than M alone, the concurrent use of the two drugs
should be avoided. The mechanism of the P-
induced increases in M toxicity in rats is unknown.
However, a pharmacokinetic interaction has been
excluded as P did not alter M plasma levels or
protein binding in either male or female non
tumour-bearing rats.
Dimethylnitrosamine-induced changes in rat liver
plasma membrane fluidity affects glucagon-stimulated
adenylate cyclase activity
Studies on the potentiation of melphalan toxicity
with prednisolone in the rat
K.G. McGhee, D.R. Newell & K.R. Harrap
DepartmentofBiochemicalPharmacology, Inst. Cancer
Res., Sutton, Surrey, England
Melphalan (M) and Prednisolone (P) are used in
combination for the treatment of a number of
human tumours. The toxicity of M and P
combinations has been studied in male and female
non tumour-bearing rats and in male tumour-
bearing (Walker 256) animals. The haematological
toxicity and lethality of i.v. M was increased in
some cases by the simultaneous administration of P
at 10mgkg-' i.p., as shown below:
G.P. Margison, A.D. Whetton, N.J.F. Dodd, L.
Needham & M.D. Houslay
Paterson Labs., Christie Hospital, Manchester, U.K.
and Biochemistry Department, UMIST, Manchester.
Dimethylnitrosamine (DMN) can act as a total
carcinogen in the liver. This ability may involve
processes complementary to the well-documented
interaction of dialkylnitrosamine metabolites with
DNA. We have explored the effects of DMN on
the important regulatory enzyme of glucagon-
stimulated cyclase (GSAC) which mediates the
hormone-stimulated vectorial flow of information
into the liver cell. DMN inhibited the activity of
this enzyme by up to 45% in the uncoupled state
and also inhibited the hormone-stimulated statePROCEEDINGS OF BACR 24TH AGM 135
after initially activiting the enzyme. Maximal effects
were observed at a DMN concentration of 15mM.
In an effort to understand the nature of this
inhibition the effect of DMN on the fluidity of
isolated rat liver plasma membranes was studied by
electron spin resonance using a spin labelled fatty
acid probe. This revealed that DMN produced a
marked rigidification of the plasma membrane
which was dose dependent with a maximal
alteration in the fluidity occurring at a
concentration of 20mM. The increase in membrane
rigidity can be demonstrated to be the cause of the
observed inhibition of GSAC. The structurally
similar non-carcinogenic DMN analog
dimethylamine hydrochloride showed no effect on
membrane fluidity, but slightly activated GSAC.
These findings indicate that DMN, via its effects on
membrane fluidity could influence plasma
membrane function and cellular response to
external stimuli. It is possible that in vivo this
property of DMN may promote the development of
cells that have been initiated by DNA alkylation.
Removal of 06-methylguanine from DNA by human,
monkey and rat tissue extracts
J. Hall, H. Bresil & R. Montesano
Unit of Mechanisms of Carcinogenesis, International
Agencyfor Research on Cancer, Lyon, France
06-Methylguanine (06-MeG), formed in DNA by
reactive intermediates of various alkylating agents,
has been shown to be a promutagenic lesion, and
its persistence in the DNA of tissues correlates with
the probability that that tissue will develop tumours
after administration of alkylating agents. In in vitro
assays, using methylated DNA as the substrate,
human, monkey and rat liver extracts were shown
to be able to catalyse the removal of 06-MeG. The
removal was specific for 06-Meg, since 7-
methylguanine and 3-methyladenine present in the
DNA substrate were not removed by the tissue
extracts. The amount of removal was proportional
to the amount of protein added and the loss of 06_
MeG occurred with stoichiometric formation of S-
methylcysteine within the protein. It was found that
human and monkey liver have similar levels of
activity (0.8mg of protein of both enzyme extracts
removed approximately 80% of the 06-MeG from
the DNA substrate) and that human liver was
about 6 times more active than rat liver. A similar
activity has also been found in monkey colon but
of a lower activity compared with monkey liver,
0.8mg of liver protein removed approximately 80%
of the 06-meG from the DNA substrate compared
with approximately 40% removal by the same
quantity of colon extract protein. The comparison
between the removal activity in other monkey tissue
extracts and human tissue extracts will be discussed.
Expression of a human osteogenic sarcoma antigen
on mitogen-stimulated human peripheral blood
mononuclear cells
M.R. Price, D.G. Campbell & R.W. Baldwin
Cancer Research Campaign Laboratories, University
ofNottingham, Nottingham NG7 2RD
In initial tests, the murine monoclonal antibody
79IT/36 against a human osteogenic sarcoma
exerted complement dependent cytotoxicity against
human peripheral blood mononuclear cells
stimulated with PHA. By flow cytofluorimetry
using a FACS IV Cell Sorter, antibody reactivity
was directed against a subpopulation ofcells judged
to be PHA-blasts by their forward angle light
scatter properties. After lactoperoxidase catalysed
radio-iodination of cells and detergent lysis,
immune complexes are isolated following the
addition of 79IT/36 antibody and Sepharose-
Protein A. The apparent molecular weight of the
labelled antigen was determined by SDS PAGE and
autoradiography to be 72,000, which is equivalent
to that of the surface antigen, p72, precipitated by
79IT/36 antibody from lysates of human osteogenic
sarcoma cells. This antigen is thus distinct from
transferrin receptors which display similar
expression in mitogen stimulated T-lymphocytes
and tumour cells and consequently it may represent
an additional cell surface marker for proliferating
human cells.
Growth of human colorectal carcinomas in vitro
S.C. Kirkland & N.A. Wright
Department of Histopathology, RPMS,
Hammersmith Hospital, Ducane Road, London W12
OHS
In order to investigate growth control in human
colorectal carcinoma cells, we have established
monolayer cultures of these cells.
Forty-seven human colorectal carcinomas, of
various histological types were collected at
operation. Cells were mechanically released from136 PROCEEDINGS OF BACR 24TH AGM
tumour pieces and plated into culture flasks in
Dulbecco's modified Eagles medium containing
10% foetal calf serum, kanamycin (100 gmlm1),
amphotericin B (1.25iugml-1) and minocycline
(1/ugml-1), Gentamicin (100 ugml-1) and penicillin
(50jugml-1) were added to this medium for the
initial culture period.
Eleven tumours were lost with bacterial
contamination, while cells from 20 of the tumours
failed to attach to the plastic culture flasks and
rapidly degenerated. Sixteen tumours yielded cells
which attached to plastic culture flasks and were of
epithelial-like morphology, 8 of these showed long
term proliferation (2-23months). To date, cell lines
have been established from 3 primary
adenocarcinomas.
When injected subcutaneously into nude mice,
these cell lines form tumours whose histology
closely resembles that of the original tumour. Two
of the 3 cells lines secrete carcinoembryonic antigen
(CEA). Confluent cultures of the mucinous
adenocarcinoma produce "domes" previously
observed in densely confluent cultures derived from
a variety oftransporting epithelia.
These cell lines will be used to test the effects of
a variety of hormones and growth factors on the
proliferation of human colorectal carcinoma cells in
vitro.
The study of two morphologically distinct lines
obtained from a metastasizing mammary
adenocarcinoma
S.C. Barnett & S.A. Eccles
Institute ofCancer Research, Clifton Avenue, Sutton,
Surrey SM2 5PX
The biological properties of cells from a murine
mammary adenocarcinoma of recent origin were
studied during serial transplantation in syngeneic
CBA/Ca hosts as the tumour progressed from a
well-differentiated, poorly metastatic neoplasm to
an anaplastic highly metastatic state. At early
generations the tumours yielded uniform cultures of
cuboidal epithelial cells which grew in polygonal
clusters. By p17, both epithelial and less cohesive
spindle type cells were obtained, and by p27 the
tumours yielded only spindle cells. However, the
original cultures of cuboidal epithelial cells did not
spontaneously alter their morphology during a
corresponding period in vitro. Early passage
tumours, and parental and cloned epithelioid cell
lines gave only pulmonary colonies after i.v.
inoculation, in contrast to late passage tumours and
spindle cell lines which showed extensive
extrapulmonary colonisation, especially in liver and
lymph nodes. The ability of the latter cells to
traverse pulmonary capillary beds was confirmed
using radiolabelled cells, and similar patterns of
dissemination and growth were seen in spontaneous
metastasis assays. In spite of the marked
phenotypic differences in these "subpopulations"
some evidence points to their being of the same cell
lineage since their electron microscopical features,
estrogen receptor levels, and lectin binding profiles
were closely comparable. Cloned lines of epithelioid
cells have been converted to spindle type
morphology by the addition of DMSO in culture.
This phenotypic modulation has remained stable so
far for 8 subsequent passages in DMSO free
medium and their biological properties are being
compared with the original cell lines.
Experimental analysis of factors affecting
distribution of metastatic tumour colonies
S.F. Juacaba, J.E. Price, K.M. Potter & D. Tarin
Nuffield Department of Pathology, (University of
Oxford), John Radcliffe Hospital, Oxford
Disaggregated cells from a large series of murine
mammary tumours have been inoculated
intravenously and intra-arterially to study both the
distribution of tumour colonies formed and the
distribution of labelled cells in the body after
vascular release. It has been found that when cells
of spontaneous murine mammary carcinomas are
injected intravenously the deposits are virtually
confined to the lungs and this accords with the
finding in animals where the tumours have spread
spontaneously. When the cells are inoculated into
the aorta it is observed that they are capable of
colonising other organs and that the individual
tumours have reproducible preferences for
establishing colonies in certain sites while
consistently not forming deposits in others. Using a
new technique involving labelling of the mammary
tumour cells with fluorescein isothiocyanate it has
been shown that they reach all organs examined
within 15min and failure of a tumour to colonise a
particular site is, therefore, not due to its cells not
arriving there.
It is concluded that the distribution of metastatic
colonies is influenced mainly by interplay between
intrinsic properties of the tumour cells and
microenvironmental influences in the organs where
they arrest.PROCEEDINGS OF BACR 24TH AGM 137
Temperature-dependent elaboration of collagenase by
the renal adenocarcinoma of the leopard frog, rana
pipiens
D.J. Ogilvie, R.G. McKinnell & D. Tarin
Nuffield Department of Pathology, (University of
Oxford), John Radcliffe Hospital, Oxford
Spontaneous renal adenocarcinomas in North-
American leopard frogs metastasise frequently
(77%) when these poikilothermic animals are kept
in a warm environment but not when they are kept
cold (Lucke and Schlumberger (1949), J. Exp.
Med., 89, 269). This provides an opportunity for
identifying factors which associate specifically with
metastatic behaviour. We have found that explants
of these tumours secrete collagenase, an enzyme
capable of dissolving connective tissue fibres and
previously found to be closely correlated with
metastatic colony-forming capability of murine
mammary tumours (Tarin, Hoyt & Evans (1982),
Br. J. Cancer, 46, 266), and that the amount
released sequentially rises and falls as the ambient
temperature is shifted between metastasis-permissive
and inhibitory levels. In contrast, normal frog renal
tissue has low collagenase output, unaffected by
temperature changes. Glucose utilisation and lactate
production are similar for normal and neoplastic
tissue at both temperatures, demonstrating that
differences in enzyme output are not simply due to
raised metabolic rate, nor to shifts in the glycolytic
pathway. The output of another tumour-associated
protease (plasminogen activator) by normal and
neoplastic frog renal tissue shows no significant
association with temperature. Hence, collagenase
output by Lucke carcinoma tissue is specifically
associated with metastasis-permissive conditions,
but further experiments are needed to test whether
the relationship is causal. The peculiar temperature-
related properties of this tumour make it potentially
suitable for studying the genetic regulation of the
metastatic phenotype.
Characterization ofclonogenic cells from human
tumour xenografts by centrifugal elutriation and flow
cytometry
T.C. Stephens, A.C. Jones, J.H. Peacock & P.
Wilson
Radiotherapy Research Unit, Institute of Cancer
Research, Sutton, Surrey, U.K.
A range of human tumour xenografts of different
histological types (pancreatic, ovarian and lung
carcinomata, and melanomas) are being
disaggregated with collagenase/pronase/DNase, and
the cells quantitatively separated using a Beckman
centrifugal elutriator, to yield fractions with
increasing peak cell volumes. Each fraction is then
tested for clonogenic potential in soft-agar,
cytological preparations are made, and samples of
cells are stained with ethidium bromide for
examination by flow cytometry. The objective is to
identify and characterize cells with high-clonogenic
potential in vitro and then to explore whether such
cells might equate with tumour stem cells in vivo.
For most of the tumours examined so far, we
have successfully identified and separated murine
host cells, but have been unable to identify a
discrete high cloning tumour cell fraction. We have
instead found that the elutriation technique yields a
good separation according to cell cycle position and
that a uniformly high cloning efficiency is observed
at all phases of the cell cycle. However, in a lung
adenocarcinoma which was difficult to disaggregate,
colony formation was associated only with clumps
of cells, perhaps indicating the unwillingness of
these cells to grow in isolation. All the tumours so
far tested have been poorly differentiated, and we
are now looking at more differentiated tumours,
and developing density gradient techniques to
complement elutriation for cell separation.
Radioimmunoprecipitation of an antigen defined by
an anti human osteogenic sarcoma antibody
D.G. Campbell, M.R. Price & R.W. Baldwin
Cancer Research Campaign Laboratories, University
ofNottingham, Nottingham NG7 2RD
The monoclonal antibody 791T/36 is known to
cross react with cells other than the immunising
791T osteogenic sarcoma cell line. On 791T cells
the 791T/36 epitope is expressed on a protein with
an apparent molecular weight of 72,000. A
preliminary investigation was performed to
determine whether the epitope occurred on similar
molecules on other cell lines. After surface labelling
various cell lines by lactoperoxidase catalysed
radioiodination and preparing detergent lysates,
immune complexes were isolated by the addition of
791T/36 antibody and Sepharose-Protein A. The
radiolabelled antigen was then characterised by
SDS-PAGE and autoradiography. The immune
precipitates from three osteogenic sarcoma cell lines
(2 OS, 788T and 278T), the prostate carcinoma
EB33T and the colon carcinoma HcLo-all138 PROCEEDINGS OF BACR 24TH AGM
previously shown to be reactive with 791T/36
antibody-each contained a protein with a
molecular weight of 72,000 as the only or major
constituent. Cell lines not cross reactive with the
antibody did not contain any antigen as detectable
by the methods used. Neuraminidase treatment of
the immune precipitates from all the osteogenic
sarcoma cells tested caused a reduction in apparent
molecular weight from 72,000 to 55,000, implying
that the 791T/36 antigen is a glycoprotein with a
high sialic acid content.
Can the differences in metastatic potential of B16
murine melanomas be explained in terms of their
glucocorticoid receptor status?
G.P. Risely & G.V. Sherbet
Cancer Research Unit, University of Newcastle upon
Tyne, Royal Victoria Infirmary, Newcastle upon
Tyne NE] 4LP
We have shown that the BL6 variant of the B16
murine melanoma, when grown as a subcutaneous
tumour in C57BL/6 mice, has a high level of
glucocorticoid receptor (GR), This differs from the
FIO variant (very low), Fl (negative) and the
parental B16 melanoma (negative). It also differs
with respect to inducibility of tyrosine amino
transferase, effects of dexamethasone on growth of
cells in tissue culture, expression of cell surface
proteins and the content of cell surface sulphydryl
groups. It seems likely that these' effects are
receptor-mediated, which is compatible with the
differences in GR status of the various lines. This
may also explain why, in our hands, the BL6
tumour is found to be metastatic, while the parental
type, FIO and Fl are nonmetastatic.
Stimulation of ovarian tumour cell clonogenicity by
mesothelial cells
A. Wilson
Department of Obstetrics & Gynaecology,
Withington Hospital, Manchester, U.K.
Mesothelial cells (MC) derived from the ascitic
fluids of patients with ovarian cancer have been
used as feeder cells in the base of a double-layer
agar system for determining the clonogenicity of
ovarian tumour cells (T). Using an ovarian tumour
cell line it has been shown that the degree of
stimulation obtained is dependent on the ratio of
MC:T. Maximum stimulation occurred at a ratio
of lOMC:IT and IOOMC:IT, with plating
efficiencies of 14% and 16% respectively in the
presence of MC compared with 0.78% and 1.7% in
their absence. MC only were not clonogenic.
Although MC have been found to produce Pg F20,
indomethacin did not abolish the feeder effect.
Treatment with 1 jgml-I of cisplatinum did not
abolish the colony-stimulating activity of these cells.
Use of 5% 02 instead of 20% 02 increased the
P.E. of the cell line but MC were still stimulatory in
low 02. Seven primary ovarian tumours have been
plated in the presence of MC and with five tumours
clonogenicity increased from 2- to 5-fold. In view of
the low frequency of ovarian cancer metastases
outside the abdominal cavity where mesothelial
cells are abundant it is possible that these cells have
an important role in the regulation of proliferation
of ovarian cancer.
The effects of growth inhibitory agents on
differentiated and malignancy-associated properties in
astrocytoma cells
M.C. Frame & R.I. Freshney
Department of Clinical Oncology, University of
Glasgow, Glasgow
Biochemical marker properties have been chosen to
represent the differentiated and malignancy-
associated astroglial phenotypes and assay systems
developed to investigate their levels of expression in
monolayer cell cultures derived from anaplastic
astrocytomas (grades III and IV, Kernohan and
Sayre histological grading). Post-confluent cultures
were exposed to a variety of drugs, whose effects
were investigated by assaying treated cells for the
biochemical marker properties.
Many of the agents studied altered the balance
between the expression of differentiated and
malignancy-associated properties in astrocytoma
cells. In particular dexamethasone, a crude extract
from pig brain, and interferon "pushed" the
phenotypic expression of the malignant astrocytes
in the direction of more mature, differentiated
astroglia; at the same time expression of
malignancy-associated properties was reduced.
Dexamethasone and pig brain extract in
combination showed enhanced activity in altering
cell phenotype over that caused by either agent
alone. The tumour promoting phorbol ester, TPA,
effectively "pushed" the phenotypic balance in the
direction of malignancy, as determined by the inPROCEEDINGS OF BACR 24TH AGM 139
vitro criteria; the differentiating properties were
unaffected by this agent. The DNA-alkylating
carcinogens, mitomycin C and methylnitrosourea,
stimulated expression of both differentiated and
malignancy-associated cell properties.
The possible relevance of these findings in
considering the growth and spread of tumours after
chemotherapy and new treatment procedures for
malignant disease will be discussed.
Toxicity and pharmacokinetic studies with CB3717
D.R. Newell, Z.H. Siddik, A.L. Jackman, P.M.
O'Connor, K.G. McGhee, M. Radacic, A.H.
Calvert & K.R. Harrap
Department of Biochemical Pharmacology, Inst.
Cancer Res., Sutton, Surrey, England
CB3717 is a folate-based inhibitor of thymidylate
synthetase (TS). Preclinical toxicity studies in mice
identified renal toxicity as the dose-limiting side
effect whilst in early clinical studies hepatic and
haematological toxicities have been observed.
Experiments have been performed in rats and mice
to determine the dose and schedule-dependency of
these effects. Renal toxicity, as indicated by
CB3717 precipitation and an increase in kidney wet
weight was observed in rats receiving >800mgm-2
given as a 2h i.v. infusion and at 330mgm-2 given
i.v. daily x 5. These doses are greater than those
currently used in man. Hepatic toxicity, as
indicated by elevations in plasma alanine
transaminase could not be demonstrated in mice or
rats following doses of less than 800mgm 2
Haematological toxicity was not observed in rats
with CB3717 given either as a 2h infusion at
1gm-2 or daily x 5 at 330mgm-2. In contrast,
methotrexate (10mgm-2 x 5) produced leucopenia
(70% control) and a depression in the red blood
cell count (60% control). Thus, rats are relatively
resistant to the haematological and hepatic
toxicities of CB3717. Experiments with 14C-CB3717
in mice have demonstrated that following
260mgm 2 i.p. 46% of the dose is excreted in the
faeces and 20% in the urine within 48h. The
material present in the urine is predominantly
unchanged CB3717 (77%). Analysis of faecal
material indicated the presence of unchanged
CB3717 (57%) and the desglutamyl metabolite
(18%). In vitro, the hydrolysis of CB3717 to this
metabolite can be catalysed by the intestinal flora
of mice. The desglutamyl metabolite of CB3717 is
not observed in the plasma of mice or rats and is
not an inhibitor of TS and, thus, probably does not
contribute to the activity or toxicity of CB3717.
Flow cytometric analysis of DNA distribution in
Lewis lung carcinoma cells after treatment with
CCRG 81010 (M&B 39565)
C. Horgan1, M.J. Tisdale', E. Erban2, M.
D'Incalci2 & S. Pepe2
'CRC Experimental Chemotherapy Group,
Department of Pharmacy, University of Aston in
Birmingham and 2!nstitute di Richerche
Farmacologische Mario Negri, Milan
Flow cytometric studies of DNA distribution allows
the determination of the number of cells in the G1,
S and G2/M compartments of the cell cycle. The
aim of this study was to compare the effects of 8-
carbamoyl-3-(2-chloroethyl)-imidazo[5,1-d]-1,2,3,5-
tetrazin-4(3H)-one (CCRG 81010; M &B 39565)
and 5-[3-(2-chloroethyl)triazen-1-yl]imidazole-4-
carboxamide (MCTIC), a potential metabonate of
the drug, on cell cycle progression in 3 LL cells.
For the initial in vitro study logarithmically growing
cultures of 3 LL cells, prepared from a primary
animal tumour were treated with equimolar
concentrations of the two agents. Flow cytometry
was performed 24h after drug treatment and again
after a further 24h recovery period in drug free
media. Both drugs at a concentration which gave
minimal cytotoxicity and little depression of
[3H]TdR incorporation produced a marked
cytotoxicity effect. Specifically the G1 fraction
decreased whereas the late S/G2M fraction
increased, a perturbation that was more
pronounced after the 24h recovery period. In the
complementary in vivo study on CCRG 81010 a
single dose of 20mgkg-1 (i.p.) to C57B1/6 mice
bearing 10 day old 3 LL carcinoma produced the
same cytokinetic effect. Determinations were made
24, 48 and 96h after treatment, there being a
progressive increase in the extent of the G, to LS-
G2-M shift and at 96h no tumour cells were
detected. The antitumour effect was evaluated by
general autopsy on day 21 after transplantation at
this time there was a 37% decrease in the weight of
the primary tumour and nearly complete inhibition
of metastases. The results obtained show that
CCRG 81010 is producing a block in the G2/M
region of the cell cycle in marked similarity to the
effects of MCTIC.140 PROCEEDINGS OF BACR 24TH AGM
Analysis of the cytokinetic effects of a bifunctional
alkylating agent in differentially sensitive human cell
lines using flow cytometry
S.W. Dean and M. Fox
Paterson Laboratories, Christie Hospital & Holt
Radium Institute, Manchester, M20 9BX, U.K.
The cytokinetic effects of nitrogen mustard on
human lymphoblasts differentially sensitive to the
cytotoxic effects have been studied using Flow
Cytometry. A dose dependent S-phase delay (up to
48h at the highest dose used) was observed in both
cell lines. The delay was greater in the more
sensitive cell line for a given drug concentration.
Fanconi's anaemia fibroblasts are more sensitive
to the cytotoxic effects of HN2 than normal human
fibroblasts. The latter showed an S-phase delay
similar to that seen in lymphoblast cell lines.
Fanconi's anaemia fibroblasts however, showed no
such delay in response to treatment.
Incorporation of [3H]-thymidine was measured
for up to 128h after treatment of the lymphoblasts
with HN2. Incorporation was seen to fall to <20%
of control levels by 12h in both cell lines and in the
more resistant cell line remained below this level for
up to 128h.
We therefore suggest that DNA synthesis and cell
cycle traverse are controlled by different
mechanisms and that incorporation of [3H]-
thymidine may not be a true reflection of DNA
synthetic activity in these cell lines.
The species dependent pharmacokinetics of DTIC
C.J. Rutty, D.R. Newell, R.B. Vincent, G. Abel,
P.M. Goddard, S.J. Harland & A.H. Calvert
Department of Biochemical Pharmacology, Inst.
Cancer Res., Sutton, Surrey, England
5-(3, 3-dimethyl-1-triazeno)imidazole-4-carboxamide
(DTIC) is a drug used in the treatment of
malignant melanoma but with very limited
therapeutic benefit. DTIC is known to undergo
oxidative N-demethylation to give 5-(3-
monomethyl- 1-triazeno)imidazole-4-carboxamide
(MIC), which then undergoes rapid chemical
decomposition yielding a methyl carbonium ion
which can methylate DNA. Thus the antitumour
activity of DTIC is dependent upon metabolism of
the drug. In view of the marked species differences
in the N-demethylation of pentamethylmelamine
(PMM) described earlier (Rutty et al. (1982),
Cancer Chem. Pharmacol., 8, 105) the metabolism
of DTIC in mouse, rat and man was examined.
DTIC and its N-demethylated metabolites, MIC
and 5-amino-imidazole-4-carboxamide (AIC) were
measured by high performance liquid
chromatography following treatment with
40mgkg-1 DTIC intravenously (i.v.) (rats and
mice) or 1200mg total dose as an intravenous
infusion (patients). The plasma half-life (tl) of
DTIC was significantly greater in the rat (35.3 min)
than in the mouse (12.7min), and greater still in
two patients studied to date (74.5 and 90min). Of
greater significance were the peak levels of MIC
found in the plasma of mice (47.5,uM) which were
some 10 times higher than in either rat (3.5,uM) or
man (5.5-7.51M). Correspondingly, DTIC shows
marked activity versus the mouse PC6
plasmacytoma when given i.v., but is without
activity against the Walker 256 tumour grown in
the rat. It is therefore tempting to suggest that the
poor clinical activity of DTIC is at least in part due
to the low level of metabolism to MIC in man.
Furthermore, these findings also suggest that the
administration of a dialkyl phenyl triazene to
patients may lead to similar difficulties in terms of
metabolism.
Response of rat mammary and prostate tumours to
treatment with a biodegradable slow-release
formulation of the LH-RH analogue, ICI 118630
B.J.A. Furr, B.E. Valcaccia & F.G. Hutchinson
ICI Pharmaceuticals Division, Alderley Park,
Macclesfield, Cheshire, SKIO 4TG
A biodegradable formulation of the peptide
analogue of LHRH, ICI 118630 (D-Ser(But)6,
AzaGly10-LHRH), has been developed which will
release active drug in animals over a period of at
least 28 days. A single implant given every 28 days
to rats with the androgen responsive, transplantable
Dunning R3327 prostate tumour caused a highly
significant reduction in tumour growth to values
identical to those in castrated animals. Twenty eight
days after the eighth implant the testes were around
10% the size of those in control animals and the
accesory sex organ weights were at castrate values.
Serum LH and testosterone were undetectable and
FSH was 30% of control values. Similar
treatment of rats with measurable
dimethylbenzanthracene-induced mammary
tumours caused marked tumour regression. In an
adjuvant setting, starting 30 days after thePROCEEDINGS OF BACR 24TH AGM 141
carcinogen before the tumours are palpable,
monthly implants of the drug will delay appearance
of tumours until at least one month after the final
treatment is given. There were no discernable
lesions at the site of implantation in any animal.
This formulation, which produces excellent
inhibition of tumour growth, should be more
acceptable clinically than daily injections.
Sensitization of EMT6 multicellular tumour
spheroids to CCNU and melphalan by hypoxic pre-
incubation with nitroimidazoles
P.R. Twentyman, P. Workman & K.A. Wright
MRC Clinical Oncology and Radiotherapeutics Unit,
MRC Centre, Hills Road, Cambridge, CB2 2QH
We have previously demonstrated (Twentyman
(1982), Br. J. Cancer, 45, 565) that the growth
delay induced in EMT6 spheroids by a range of
cytotoxic drugs is enhanced when the spheroids are
pretreated under hypoxic conditions with 5mM
misonidazole (MISO) for a period of 3-5h. The
studies have now been extended to MISO
analogues differing in electron affinity (El) and
octanol/water partition coefficient (P.C.). The 2-
nitroimidazoles SR-2508 (El= -388mV,
P.C.=0.046) and Ro 07-1902 (El=-391 mV,
P.C. =2.5) were equally effective as MISO
(E1 -389nV, P.C. =0.43) in sensitizing to CCNU
with 5h hypoxic pre-incubation at 5mM. However
the 4-nitroimidazole AM-1 (El =-564mV,
P.C.=0.44) was ineffective as a sensitizer to CCNU
in such a regime. It therefore appears that electron
affinity is the predominant factor for sensitization
to CCNU in vitro and that lipophilicity is much less
important. This is the opposite conclusion to that
which we have reached for tumour sensitization in
vivo to CCNU (Workman & Twentyman (1982),
Br. J. Cancer, 46, 249). At a reduced concentration
of 0.5mM of MISO (=lOO1gml-') little if any
sensitization of spheroids to CCNU was seen with
16h of hypoxic preincubation. This exposure
approximates that produced in patients following a
single dose of 3gm 2 of MISO. Similarly no
enhancement of CCNU response was produced by
16h at 100 igml-I hypoxic pre-incubation with
either SR-2508 or Ro 07-1902. These sensitizer
regimes did, however, considerably enhance the
subsequent response of spheroids to melphalan.
Some increased sensitivity to melphalan was
produced by 16h pre-incubation under hypoxia
alone. The additional sensitization due to the
presence of the nitroimidazoles again showed little
dependence upon lipophilicity.
The effects of retinoic acid analogues on the growth
and metastases of murine sarcomas and carcinomas
S.A. Eccles
Division of Tumour Immunology, Institute of Cancer
Research, Sutton, Surrey
A study was made of the effects of retinoids on the
growth (in vitro and in vivo) and spontaneous
metastasis of a variety of murine sarcomas and
carcinomas. Tumour-bearing mice were dosed
orally with 40mgkg-1 Tigason Ro-9359 daily
throughout tumour growth, and cell cultures were
treated with 10-6 and 10-8M concentrations of the
same retinoid.
Certain of the tumours studied (notably
immunogenic sarcomas and carcinomas) responded
to retinoid treatment in vivo by slower growth rates
and in some cases complete regression, whereas
non-immunogenic tumours were unaffected. In
vitro, retinoid treatments generally were without
significant effect, and where any growth inhibition
was seen it did not correlate with in vivo tumour
responsiveness. The data suggested that in these
systems the in vivo effects of retinoids on tumour
growth were mediated indirectly, possibly in their
role as immunopotentiators. This was further
supported by experiments showing that
immunosuppression abolished the retinoid
inhibition of tumour growth, and prior
immunisation enhanced the effect. Ro-9359
administration during tumour growth did not
significantly inhibit the subsequent development of
spontaneous metastases of non-immunogenic
tumours, but decreased the incidence of secondary
disease of tumours of moderate immunogenicity. It
was also found that retinoid treatment inhibited the
induction of tumour metastasis caused by whole
body X-irradiation, but not that by Cyclosporin A.
These and other data suggest that the retinoid
effects observed were due to stimulation of host
anti-tumour effector cells, possibly mononuclear
phagocytes.
Effects of single dose misonidazole on the
pharmacokinetics of CCNU in mice
F. Lee & P. Workman
MRC Clinical Oncology and Radiotherapeutics Unit,
MRC Centre, Hills Road, Cambridge, CB2 2QH
Using a high performance liquid chromatography
(HPLC) method we have investigated the effect of142 PROCEEDINGS OF BACR 24TH AGM
misonidazole (MISO) on the pharmacokinetics of
CCNU in mice. CCNU and MISO were given at a
dose of 20mgkg-' i.p. and 500mgkg-' i.p.
respectively. In the absence of MISO the plasma
clearance kinetics of CCNU were biphasic-the tfca
was 2.3min and the t2Lf was 53min. MISO given
30min before CCNU prolonged the tl2o by a factor
of 2.6 but had no effect on t2Lf. Moreover, the
apparent volume of distribution was decreased by a
factor of 1.6. As a result, the plasma area under the
curve (AUC) was increased by a factor of 1.7. The
AUC for the total active metabolites was increased
by a similar amount. Further, the MISO dose-
response relationship for pharmacokinetics changes
was similar to that for chemosensitization. Studies
with 4 tumours, the KHT, RIF-I and EMT6 mouse
tumours and the HT29 human tumour xenograft,
showed that MISO raised the tumour
concentrations of CCNU by 2-2.5 times. Detailed
studies in the KHT tumour showed that there was
a lag period before peak tumour CCNU
concentrations were reached and that MISO
increased the peak concentration by a factor of 2.4.
In contrast, studies with critical normal tissues, the
gut and the bone marrow, have shown that MISO
did not increase the peak CCNU concentration in
these tissues. This differential effect of MISO on
peak CCNU concentrations of tumour and normal
tissues is probably responsible for the enhancement
of tumour toxicity and the therapeutic gain seen in
in vivo chemosensitization experiments.
Enteroglucagon neither promotes carcinogenesis nor
stimulates colonic cell turnover in defunctioned rat
large bowel
J.B. Bristol, M.A. Ghatei, S.R. Bloom & R.C.N.
Williamson
Department ofSurgery, Bristol Royal Infirmary, and
Department of Medicine, Royal Postgraduate
Medical School, London
Small bowel resection promotes adaptation and
enhances carcinogenesis in rat colon (Williamson
(1979), Ann. Roy. Coll. Surg. Engl., 61, 341). It is
also associated with increased levels of plasma
enteroglucagon and increased cell proliferation in
small bowel sequestered from the faecal stream
(Sagor et al. (1982), Br. J. Surg., 69, 14). The effect
of luminal and systemic factors on colonic cell
proliferation and carcinogenesis was studied in rats
given either a defunctioning transverse colostomy
(n =34) or sham colostomy (n = 15) followed by 6
weekly injections of azoxymethane (AOM)
15mgkg-1 body weight. Rats with colostomy then
underwent 85% jejunoileal resection (JIR) or sham
resection; those with sham colostomy also had a
sham JIR and acted as controls. Tumour yield and
colonic crypt cell production rate (CCPR) were
studied in the defunctioned segment or its
equivalent 30 weeks later, when plasma
enteroglucagon was estimated. Median tumour
yield in defunctioned colon fell from 2 to 0 after
colostomy (P<0.05) and was unaffected by JIR.
CCPR in control rats was 5.6+0.4 cells/crypt/hour,
falling to 1.2+0.6 after colostomy (P<0.05). It too
was unaffected by subsequent JIR. Plasma
enteroglucagon rose very slightly after colostomy
(97.1 + 17.9pmoll-1 versus 127.5+19.1 pmoll-1,
N.S.). After JIR plasma enteroglucagon doubled
(232.1 +23.7pmoll-1; P<0.01). Despite increases
in plasma enteroglucagon after JIR, neither CCPR
nor tumour yield was altered in defunctioned colon.
Luminal factors must therefore predominate in
maintaining cell turnover and promoting
carcinogenesis in rat large bowel.
Morphological changes occurring during prolonged
organ culture of colonic mucosa from normal rats
and from rats pretreated with dimethylhydrazine in
vivo
P.V. Senior, J.P. Sunter, D.R. Appleton1 & A.J.
Watson
'Departments of Pathology & Medical Statistics,
University ofNewcastle upon Tyne
Rats treated with the carcinogen dimethylhydrazine
(DMH) develop multiple colonic tumours preceded
by a distinct phase of crypt hyperplasia. Using a
development of a system which permits prolonged
maintenance of murine and human mucosae in
organ culture, we have studied the morphological
changes in control and treated tissue for up to 25
days. Multiple explants were set up on cellulose
acetate filters and maintained in Waymouth's
medium supplemented with ascorbic acid, ferrous
sulphate and hydrocortisone in 95% 02 5% CO2 at
37°C and rocked at 8 cyclesmin- . Prior to culture
treated mucosae taken at 4-8 weeks after treatment
showed hyperplastic and dysplastic crypts. During
the first 5 days in culture progressive loss of mucin
from crypt cells together with crypt shortening was
seen in both groups and displastic crypts were no
longer apparent in the treated tissue.
Ultrastructural preservation was good but
intercellular spaces were enlarged. Some loss of
crypts was seen possibly due to the initial trauma.PROCEEDINGS OF BACR 24TH AGM 143
Crypts lined with a single layer of columnar cells
were observed until the end of culture at 25 days;
however in both control and treated tissue tortuous
"adenomatous" crypts began to appear from about
10 days onwards. In the crypts of both groups
mitotic activity was restricted to the basal two-
thirds but mitoses were seen in the surface
epithelium overlying areas of crypt loss. We
conclude that prolonged maintenance of colonic
tissue is possible even in a simple system such as
this but that neoplastic transformation in vitro does
not occur following carcinogen pretreatment in vivo.
Carcinogenesis in defunctioned rat colon: The effect
of bile acid irrigation
J.B. Rainey, J.B. Bristol & R.C.N. Williamson
University Department of Surgery, Bristol Royal
Infirmary, Bristol
The presence of faeces and its composition are
important in colorectal carcinogenesis (Campbell et
al. (1975), Cancer Res., 35, 1365). Bile acids, in
particular, have been implicated as cocarcinogens in
animals and man (Reddy (1975), Cancer, 36, 2401).
In 40 male Sprague-Dawley rats, a long segment of
colon was isolated as a Thirty-Vella fistula (TVF).
Twenty-five TVFs were irrigated 3xweekly for 12
weeks with a 0.12M solution of the secondary bile
acid sodium deoxycholate (SDC). The remaining
TVFs, (n= 15), were not irrigated. Other rats
underwent colonic transection and reanastomosis
(sham TVF, n=15). Operations were performed
one week after a course of azoxymethane (total
dose 90mgkg-' i.p.). Results at sacrifice (22
weeks):
No. of Tumour
colonic tumours % tumours diam (mm)
(mean xs.e.m.) in left colon (mean+s.e.m.)
Sham TVF 4.3+0.6 81 4.7+0.3
TVF alone 2.6+0.3* 51 4.4+0.6
TVF+SDC 2.6+0.4* 58 2.6+0.4**
*P<0.05 vs shams.
**P<0.01 vs other groups.
Carcinogenesis was reduced in defunctioned colon
probably because of mucosal atrophy and the
normal left sided preponderance of tumour yield
was abolished. SDC irrigation did not affect the
TVF tumour yield and indeed resulted in smaller
tumours. This unexpected protective effect may
reflect a detergent role in cleansing the TVF.
Alternatively, bile acids may exert their suggested
cocarcinogenic effect only in the presence of faeces,
anaerobic bacteria, or other, as yet unidentified,
faecal constitutents.
The role of faecal bile acids (FBA) in large bowel
carcinogenesis
M.J. Hill, B.C. Morson & M.H. Thompson
PHLS-CAMR, Porton Down, Salisbury and St.
Mark's Hospital, London EC]
Large bowel carcinogenesis is a multi-stage process
involving adenoma formation, adenoma growth
and the development of increasingly severe
dysplasia and finally neoplasia. There is a strong
correlation between the risk of large bowel
carcinogenesis and FBA concentration; this
correlation reflects the risk associated with high
fat/high protein diets and is further enhanced by
the observation that in vitro faecal organisms
(termed NDC) possess the ability to degrade bile
acids to carcinogen-like precursers. In our case-
control studies 70% of 120 bowel cancer cases had
elevated FBA concentrations and carriage rates of
NDC compared with 10% of 116 patients with
non-malignant bowel disease; the FBA/NDC
discriminant was very much better with early than
with advanced metastatic cancers, and was also
better for tumours of the left than of the right
colon.
In a study of 150 patients with colorectal
adenomas there was a significant correlation
between FBA concentration and adenoma size and
the severity of their dysplasia, indicating that bile
acids may be directly involved in promotion of the
precurser state. In a study of 105 patients with
ulcerative colitis of more than 10 years duration,
those who developed severe epithelial dysplasia and
carcinoma of the colon had higher FBA
concentrations than those who did not, indicating
that the bile acids might also be important in the
carcinogenesis in these patients.
Goblet cell changes during intestinal adaptation to
azoxymethane and enteric bypass
J.B. Bristol, I.O. Olubuyide & R.C.N. Williamson
University Department of Surgery, Bristol Royal
Infirmary
Jejunoileal bypass (JIB) promotes the development
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of experimental colorectal cancer, probably by
enhancing mucosal cell turnover (Bristol et al.
(1982), Proc. Am. Assoc. Cancer Res., 23, 60).
Chemical carcinogenesis in rats is associated with
increased numbers of goblet cells containing
sialomucins (Filipe (1975), Br. J. Cancer, 32, 60),
and JIB itself may have a similar effect (Olubuyide
et al. (1982), Gut., 23, A881). Adaptive changes,
mucin histochemistry and tumour yields were
therefore studied in male Sprague-Dawley rats
(n=45) 30 weeks after 85% JIB (end-to-side) or
sham bypass. Weekly s.c. Injections of
azoxymethane were given (total dose 90mgkg-1),
starting 6 weeks preoperatively. Controls had
vehicle injections followed by sham bypass.
Azoxymethane alone increased length and weight of
duodenum and colorectum by 5-34% and colonic
crypt depth by 10-15% (P<0.05). The number of
goblet cells containing sulpho- and sialo-mucins
was consistently increased throughout the intestine
(by 14-40%). After JIB+azoxymethane, all values
were further increased, despite a 27% reduction in
body weight. Thus duodenal and colorectal length
and weight were 16-212% greater, colonic crypts
were 20-30% deeper and acid-mucin goblet cells
were 6-40% commoner (P=0.02-0.001); maximal
increments occurred in sialomucins in the distal
colon. Moreover, JIB doubled the yield of large-
bowel tumours (4.3 versus 2.2 per rat: P<0.01).
The carcinogen (azoxymethane) and co-carcinogen
(JIB) share the ability to cause intestinal
hyperplasia, increasing in particular the number of.
colonic goblet cells that contain sialomucins.
Comparative studies on the relative mutagenicities of
Aflatoxin B -DNA adducts in a bacterial plasmid
S.C. Booth and R.C. Garner
Cancer Research Unit, University of York, York
YOJ 5DD
Aflatoxin B1 (AFB1), the major mycotoxin
produced by certain strains of Aspergillus flavus, is
a potent mutagen and animal carcinogen.
Epidemiological evidence supports the concept that
AFB1 is also a human liver carcinogen. AFB1 can
be activated by mono-oxygenase enzymes or by
peroxoacids to give AFB1-8,9-oxide which can
chemically react with nucleic acids to form as a
major adduct 8,9-dihydro-8(7-guanyl)-9-hydroxy
AFB . This reaction, which arises through
electrophilic attack at the N7-position of guanine,
leads to an adduct which is unstable because of the
protonated N7-position. As a result the guanine
adduct can give rise to (1) a guanine imidazole
ring-opened form (iro AFB1-DNA), (2)
depurination through loss of the AFB1-gua residue,
and (3) loss of AFB1-8,9-diol. Of these several
pathways it is not known which are of biological
importance. To try and answer this question we
have compared the relative survival and
mutagenicity of plasmid pK0482 which has been
reacted with AFB1 and then transformed into E.
coli AB1886 (uvrA-). Plasmid pK0482 carries both
ampicillin resistance and GalK genes. Mutants in
which the GalK gene has been inactivated appear
white when grown on galactose/ampicillin
MacConkey agar plates while normal transformants
appear red. Ring-closed and ring-opened forms of
the AFB1-DNA adduct resulted in equal amounts
of plasmid inactivation and mutation. To enable
these results to be interpreted correctly, further
experiments into the intra-cellular stability of ring-
closed AFB1-DNA and into the presence and
mutagenicity ofapurinic sites are being undertaken.
Studies on the macromolecular binding of [3H-
acetyl]benzidine and benzidine derived azo dyes in
vitro and in vivo
J.C. Kennelly and C.N. Martin
Cancer Research Unit, University of York
Acetylation to produce N-acetylbenzidine (ABZ) is
the first stage in activation of the human
carcinogen benzidine (BZ). N-OH-diacetyl-benzidine
(N-OH-DABZ) is the proximate carcinogenic
species formed from ABZ in the presence of rat
liver S9 in vitro. The activation of ABZ in vivo
however proceeds along a different route. This
study used rat liver slices to determine by DNA
adduct analysis whether metabolism of ABZ in this
system proceeded as in vivo. Overall binding to
DNA was measured in hamster and rat liver at 24
and 168h following IP injection of ABZ at
25mgKg-1 (rat 70.8 and 27.8pmolmg-1 DNA,
hamster 33.0 and 14.1 pmolmg-I at 24 and 168h
respectively) and in liver slices 100jugg- liver (rat
53.1, hamster 27.4pmolmg-1). Adduct analysis
revealed the same adduct was present in each case,
identified as N-(deoxyguanosin-8-yl)-N'-
acetylbenzidine. The results suggest that, unlike S9
metabolism where sulfotransferase activity on N-
OH-DABZ would lead to diacetylated DNA
adducts, metabolism of ABZ in liver slices is similar
to that occurring in vivo. Direct blue 6 is a potent
rat hepatocarcinogen whereas congo red appears to
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BZ and are activated by reduction releasing the free
amine. Both dyes are readily reduced by gut
microflora but only Direct blue 6 is reduced by rat
liver. Animals were gavaged or IP injected with
[3H] labelled dyes and liver DNA binding
measured. In both cases Direct blue 6 bound to a
greater extent implicating liver azo reductase
activity in determination of carcinogenic potency.
Covalent binding of ultimate carcinogens to
glutathione transferase B in vitro
B. Coles", D. Meyer1, B. Jernstrdm2, F. Beland3 &
B. Ketterer1
'Courtauld Institute of Biochemistry, Middlesex
Hospital Medical School, London, 2Department Of
Forensic Medicine,' Karolinska Institute, Stockholm
and 3National Center for Toxicological Research,
Arkansas, U.S.A.
Glutathione (GSH) transferase B was isolated
because of its ability to react with a metabolite of
N,N-dimethyl-4-aminoazobenzene (DAB) in vivo.
Two of its properties concern us here: it is (1) a
non-covalent binding protein for hydrophobic
ligands and (2) an enzyme of detoxication. GSH
transferase B might be expected to bind
electrophilic metabolites of carcinogens initially by
noncovalent forces and then either to react with the
electrophile or catalyse its GSH conjugation. Three
ultimate carcinogens were studied:
+(anti)benzo(a)pyrene-7,8-diol-9,10-oxide (BPDE),
N-sulphonyloxy-N-acetyl-2-aminofluorene (AAF-N-
sulphate) and aflatoxin B,-2,3-oxide (AFB,-oxide).
The first two were synthesized chemically and the
last two biosynthetically by a microsomal system.
BPDE and AFB,-oxide do not react non-
catalytically with GSH; AAF-N-sulphate reacts
with GSH non-catalytically but is not a substrate
for GSH transferase B. Covalent reaction has been
studied with the two subunits which compose GSH
transferase B; YaYC. In the absence of GSH, BPDE
reacted only with Ya (as does DAB in vivo) while
AAF-N-sulphate and AFB,-oxide reacted with both
Ya and Yc. In the presence of GSH, the resulting
enzymic activity almost completely prevented the
reaction of BPDE with the enzyme protein, but was
only partially effective in preventing the reaction of
AFB1-oxide with the protein. Although AAF-N-
sulphate was not a substrate for the enzyme, non-
catalytic reaction with GSH was sufficient to cause
substantial reduction in reaction with enzyme
protein. These results show that GSH and GSH
transferase B are potent in detoxifying BP but
much less so for AFF or AFB,. These properties
may be important determinants in carcinogenesis
e.g. AFBI and AAF are powerful
hepatocarcinogens in the rat while BP is not.
Studies on the fate of alfatoxin-8,9-epoxide
E.J. Moss, G.E. Neal and D.J. Judah
Toxicology Unit, Medical Research Council
Laboratories, Woodmansterne Road, Carshalton,
Surrey, U.K.
The reactive intermediate of the potent hepatotoxin
and hepatocarcinogen alflatoxin B, (AFB1) is
believed to be the AFB1-8,9-epoxide. The reaction
of the epoxide with DNA is an important event
which has received widespread attention.
Alternative fates for the epoxide may include
conjugation, hydrolysis to AFB1-8,9-dihydrodiol,
and protein interaction, possibly by electrophilic
attack of the epoxide on nucleophilic sites in the
protein or by the interaction of the ring opened
form of the diol (AFB,-dialdehyde) with the free
amines of protein via Schiffs base formation.
We have recently observed that an important
detoxification pathway for the epoxide involves
formation of an S-linked glutathione conjugate
involving glutathione-S-transferase B. The
conjugate (AFB,-GSH) has been identified by
proton n.m.r. and mass spectral studies, and further
enzymic degradation allowed the identification of
other aflatoxin conjugates. The cysteinylglycine
conjugate (AFB,-Cys Gly) produced by y-
glutamultranspeptidase activity on AFB,-GSH, was
further degraded by dipeptidase. The material
produced was identified as the cysteinyl conjugate
(AFB,-Cys) from proton n.m.r. data.
Analysis of these polar metabolites of AFB, by
reverse phase HPLC has allowed investigations into
their production by several systems. AFB1-Cys has
been investigated both as an expected degradation
product of AFB1-GSH in vivo and also as a
possible marker to investigate the interaction of
AFB,-8,9-epoxide with protein sulphydryl groups.
Sequential analysis of hyperplastic liver lesions
induced by aflatoxin B, and partial hepatectomy,
using GGT as a marker
M.M. Manson & G.E. Neal
MRC Toxicology Unit, Carshalton, Surrey SM5
4EF
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model for sequential analysis of liver carcinogenesis
used an in vivo system involving a single
carcinogenic dose of diethylnitrosamine, partial
hepatectomy (PH) and short term dietary exposure
to 2-acetyl-aminofluorene. We have examined a
similar, but essentially simpler, system using only
one carcinogen, Aflatoxin B1, with particular
reference to its effect on y-glutamyl transpeptidase
(GGT). Untreated or AFB1-fed (4ppm) male
Fischer 344 rats underwent PH and were returned
either to control or AFB1 diet or received a single
i.p. injection ofAFBV. GGT levels and distribution
were compared in the same animal before and after
PH. Animals fed AFB1 long enough to develop
GGT positive foci were much more resistant to a
single i.p. injection of AFB1 administered 24h after
PH. However, both untreated and fed animals
survived well when returned to an AFB1 diet after
PH. GGT levels in untreated animals returned to
control diet were elevated (x 2) when examined 3
days or 1 week after PH, but only very slightly at
18 h. The increased enzyme activity was
histochemically apparent in bile ducts and
periportal hepatocytes. In AFB1-fed animals the
percentage increase in GGT 3 days or 1 week after
PH increased with time on AFB1 diet before the
operation. GGT levels at 18h post-PH were lower
than before the operation in fed animals.
Histochemistry showed that the size and number of
foci increased after PH. We are using this system to
examine the development of AFB1-induced
hepatocarcinogenesis and the relationship of GGT
to this process.
Monoclonal antibodies to normal hepatocytes reveal
similarities in phenotypes expressed during
development and hepatocarcinogenesis
C.H. Holmes, B. Gunn, E.B. Austin, A. Fisk, M.J.
Embleton & R.W. Baldwin
Cancer Research Laboratories, University of
Nottingham, Nottingham NG7 2RD
In an attempt to probe the cellular events
associated with hepatocarcinogenesis we have
produced a panel of monoclonal antibodies, 3 of
which are directed against normal adult rat
hepatocytes. We have used an
immunohistochemical technique to examine the
reactivity of these antibodies with normal adult
liver, with developing foetal and neonatal liver and
with azo-dye induced premalignant and malignant
liver lesions including a range of 32 primary liver
carcinomas. Monoclonal antibody RL24/72 stained
hepatocytes and other hepatic parenchymal cells in
frozen sections of normal adult liver. Staining with
this antibody was detectable from 17 days gestation
onwards. Most tumours showed some reactivity
with RL24/72. Monoclonal antibody RL23/36 was
specific for hepatocytes within the normal liver. The
adult pattern of staining with this antibody was not
observed until parturition. All tumours showed
reduced staining with RL23/36 and many showed
no reactivity. While monoclonal antibody RL16/79
was also specific for hepatocytes, only hepatocytes
surrounding central veins were stained by this
antibody, periportal hepatocytes were not. The
adult staining pattern characteristic of this antibody
was not established until 4 weeks post partum. Only
2 liver carcinomas were stained by RL16/79. The
types of staining observed with these monoclonal
antibodies in malignant and also in premalignant
liver lesions indicate that re-expression of foetal
phenotypes may occur during liver carcinogenesis.
Monoclonal antibodies against B-cell non Hodgkin
lymphomas (N.H.L.)
E.M. Rankin, A. Kekman, F.A. Vyth-Dreese, J.G.
McVie & R. Somers
The Netherlands Cancer Institute, Plesmanlaan 121,
1066 CX Amsterdam, The Netherlands
We have identified 3 monoclonals with different
degrees of specificity for malignant lymphomas.
Lymphocyte cell membranes from the pleural
effusion of a patient with centrocytic/centroblastic
N.H.L. were used to immunise a Balb/c mouse, the
spleen cells of which were fused with Sp 2/0
myeloma cells. Two monoclonals, M1 and M2,
were obtained, both IgG1. Both antibodies react
with the immunising cells, but not with pooled
human T and B lymphocytes, monocytes,
erythrocytes, granulocytes, sections of thymus,
spleen or lymph node, nor with the cell lines HSB,
CEM, NALM-1, SB and U937, using enzyme-
linked immunoabsorbent assay, indirect membrane
immunofluorescence or immunoperoxidase staining
on thin sections. There was no reaction between
Ml and 13 lymphomas of different morphology.
The Ml antibody did not react with cultured
autologous T cells. In contrast to M1, M2 reacted
with pooled immunoglobulins and free K light
chains and the EBV-transformed B cell line JY.
Immunofluorescence with M2 showed staining in 4
of 9 lymphomas. The reaction was not correlated
with the presence of K light chain. Immunisation
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centrocytic/centroblastic N.H.L. patient yielded one
antibody LI. This reacts with the lymphocytes of
the immunising patient but not with pooled T or B
lymphocytes or U937 cells. In 3 cases of lymphoma,
immunofluorescence showed that more than 50%
cells were strongly positive, in 4 smaller numbers of
cells were stained, and there was no reaction in 4
cases. There was no correlation between reactions
with MI, M2 and LI and known surface markers
including immunoglobulin, K or A light chain, BAl
and BA2. MI is highly specific for the immunising
cells in contrast to M2 and LI, which may be
useful in the elucidation of B cell differentiation
pathways.
Isolation and characterization of cytotoxic effector
cells infiltrating spontaneous rat tumours
B.L. Ferry, G.R. Flannery, R.A. Robins & R.W.
Baldwin
Cancer Research Campaign Laboratories, University
ofNottingham, Nottingham NG7 2RD
The proposition that natural killer (NK) cells
mediate surveillance mechanisms in vivo against
primary tumour development and metastatic
tumour spread has recently received additional
support (Warner & Dennert (1982), Nature, 300,
31). In this respect, it might be expected that NK
cells would be present in the infiltrates of primary
and secondary tumours.
We have examined the infiltrates of primary and
transplanted spontaneous rat tumours using
immunohistology and separation on velocity
sedimentation gradients. Of 12 spontaneous
tumours, 9 yielded cytotoxic effector cells which
lysed the rat myeloma Y3Ag in a 6h chromium
release test. (i) These effector cells were
heterogeneous in size: all positive populations
included cytotoxic small lymphocytes, but killing
was also mediated in some tumours by larger cells,
possibly cytotoxic macrophages. (ii) Cytolytic
activity was generally lower than that of splenic
NK cells and low yields correlated with histological
patterns. (iii) In situ suppression is likely and both
effector cell types responded in vitro to activation
by interferon. (iv) Monoclonal antibody staining and
positiveselectionbyFACSindicatedthatmosteffector
lymphocytes were OX-8 positive, in keeping with
splenic NK cells (Cantrell et al. (1982), Immunol., 45,
97) but some experiments suggested that an OX-8
negative population was also present. Further hetero-
geneity is demonstrated by cell sorting experiments
withW3/13 antibodywherebothpositiveandnegative
populations mediate killing. These data indicate
that spontaneous tumours are infiltrated by
cytotoxic effector cells which are heterogeneous and
include various phenotypic subsets of NK cells.
In vitro activation of natural killer cell activity: Its
possible relation to in vivo rejection of tumours using
non-cytotoxic T cell subsets
V. Britten, R.A. Robins & R.W. Baldwin
Cancer Research Campaign Laboratories,
Nottingham
An assay has been developed to monitor in vitro
boosting of rat natural killer (NK) cell activity
using in vivo primed lymphocytes as a source of T
"helper" cells.
This work is being done to identify in vitro
correlates for in vivo experiments, done in our
laboratory and elsewhere, which show that
activated T "helper" cell subsets are important in
the rejection of immunogenic tumours (or
allografts) (Fernandez-Cruz et al. (1982), J.
Immunol., 128, 1112; Loveland and McKenzie
(1982), Immunol., 46, 1313) in adoptive transfer
tests.
The T cell subpopulation necessary for this
activity is reactive with W3/25 monoclonal
antibody. This W3/25 positive subpopulation
contains no cytotoxic T cells, NK cells, or their
precursors. These cells may function by activation
of other lymphocyte subsets at the tumour site, or
by recruitment from other areas. As NK cells are
known to be present in the rat tumours under
study, (Ferry et al. (1983) Br. J. Cancer, 48, 111) we
wished to investigate whether tumour rejection
might be induced by activation of NK cells by
specifically triggered non-cytotoxic T cells.
T lymphocytes primed in vivo using BCG or
tumour, were incubated in the presence of the
appropriate antigen, with normal rat spleen cells as
a source of NK precursors. Increased killing of NK
targets could be demonstrated, when compared
with the activity generated by activated
lymphocytes incubated without the specific antigen
or when normal lymphocytes were used as a source
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Native and inducible levels of natural cytotoxicity in
lymph nodes draining human mammary carcinoma
I. Kimber1, M. Moore', A. Howell2 & M.J.S.
Wilkinson2
1Department of Immunology, Paterson Laboratories
and 2Department of Medical Oncology, Christie
Hospital and Holt Radium Institute, Manchester
M20 9BX
Although suggestions that NK cells mediate innate
host resistance to malignant development are
attractive, it is difficult to reconcile such hypotheses
with the reported paucity of natural cytoxic
function exhibited by lymph node cells (LNC).
To further investigate the role of local NK cell
function in malignancy we have examined the
natural cytotoxic potential of lymphocytes isolated
from axillary nodes draining mammary carcinoma.
Although less reactive than peripheral blood
lymphocytes LNC possess variable natural
cytotoxic capacity. Augmentation of LNC by
interferon (IFN) is also variable with only some
populations displaying potentiated lysis following
exposure to either IFN-a or gene-cloned IFN-o2.
Where present the IFN-induced augmentation of
LNC cytotoxicity was invariably weaker than that
observed following similar treatment of
autochthonous peripheral blood mononuclear cells.
Irrespective of their responsiveness to IFN the
cytotoxic capacity of all LNC preparations
examined was significantly increased following pre-
incubation with either Staphylococcal enterotoxin
A (SEA) or factors elaborated by lectin-pulsed
allogeneic LNC. The induction or amplification of
LNC-mediated natural cytotoxicity by lymphokines
may provide a local potentiation of natural immune
function at the host:tumour interface.
The relationship between lipid metabolism and
immune depression in a tumour model
R. Windle
Department of Surgery, Leicester Royal Infirmary,
Leicester
Serum triglyceride (TG) levels are raised in both
human and experimental cancer (Dilman et al.
(1981), Br. J. Cancer, 43, 637). Fatty acids depress
the mitogenic response of lymphocytes in vitro
(Mertin and Hughes (1975), Int. Archs. Allergy,
Appl. Immun., 48, 203) and a diet rich in
polyunsaturated fats increases chemical
carcinogenesis (Hopkins et al. (1978), J. Natl
Cancer Inst., 60, 849). Therefore, it has been
suggested by Dilman et al. that high TG levels may
predispose to malignancy by causing a depression
of host immunity. To investigate this hypothesis,
TG and free fatty acid (FFA) levels have been
measured during the growth of colonic tumours
induced in rats by dimethylhydrazine and the
results have been correlated with changes in cellular
and humoral immunity.
Studies were performed at 8 weekly intervals
after tumours appeared at 32 weeks in 4 groups of
12 rats. Cellular immunity was assessed by
lymphoblast transformation in response to PHA
using a whole blood method and humoral
immunity was studied by measuring antibody titres
to sheep red cells by agglutination.
Serum FFA levels became reduced at 40 weeks
(0.36mmoll-1 range 0.25-0.48 from 0.69mmoll-P
range 0.56-0.85). Serum TG levels became elevated
at 48 weeks (4.1 mmol1-1 range 3.6-4.6 from
3.2mmol 1- I range 2.5-3.8).
Responsiveness to PHA became depressed at 40
weeks and antibody production was reduced at 56
weeks and these results were not affected by
correction of the FFA and TG levels by heparin. It
is concluded that in this tumour model, depression
of immunity is not dependent upon changes in fat
metabolism alone.